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Abstract
Hashimoto's thyroiditis (HT) is an organ-specific T-cell mediated disease. It is a complex disease,
with a strong genetic component. To date, significant progress has been made towards the
identification and functional characterization of HT susceptibility genes. In this review, we will
summarize the recent advances in our understanding of the genetic input to the pathogenesis of
HT.
Introduction
Hashimoto's thyroiditis (HT) is one of the most common
human autoimmune diseases responsible for considera-
ble morbidity in women [1]. It is an organ-specific T-cell
mediated disease that affects the thyroid, and genetics
play a contributory role in its complexity. To date, signifi-
cant progress has been made in identifying and character-
izing those genes involved in the disease. In this review,
we will summarize recent advances in our understanding
of the genetic contribution to the pathogenesis of HT.
Epidemiology and clinical features of Hashimoto's 
thyroiditis
Goitrous autoimmune thyroiditis, or Hashimoto's thy-
roiditis is a common form of chronic autoimmune thy-
roid disease (AITD). The disorder affects up to 2% of the
general population [2] and is more common in older
women and ten times more frequent in women than in
men [3]. In the NHALES III study, performed in the USA,
the prevalence of subclinical and clinical hypothyroidism
was 4.6% and 0.3% respectively [4]. Another US epidemi-
ological study, the Whickham survey, showed the preva-
lence of spontaneous hypothyroidism to be 1.5% in
females and less than 0.1% in males [5]. These prevalence
rates are similar to those reported in Japan [6] and Finland
[7]. A significant proportion of patients have asympto-
matic chronic autoimmune thyroiditis and 8% of woman
(10% of woman over 55 years of age) and 3% of men have
subclinical hypothyroidism [8]. According the data of the
20-year follow-up to the Whickham survey cohort, the
risk of developing overt hypothyroidism is four times
higher in women aged between 60 and 70 years than for
women between 40 and 50 years of age [1].
Subclinical hypothyroidism is characterized by an
increase in serum thyrotropin (TSH) whilst serum levels
of thyroxine (T4) and triiodothyronine (T3) remain nor-
mal. The overt disease is defined by the dramatic loss of
thyroid follicular cells (thyrocytes), hypothyroidism, goi-
tre, circulating autoantibodies to two primary thyroid-
specific antigens, thyroglobulin (Tg), thyroid peroxidase
(TPO), and lowered concentrations of serum TSH and T4
[9]. Histological and cytological features of HT include a
dense thyroidal accumulation of lymphocytes, plasma
cells and occasional multinuclear giant cells. The epithe-
lial cells are enlarged, with a distinctive eosinophilic cyto-
plasm, owing to increased number of mitochondria [10].
HT has been shown to often coexist with other autoim-
mune diseases such as type 1 diabetes (T1D), celiac
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disease, rheumatoid arthritis, multiple sclerosis, vitiligo,
etc [11-14]. HT can also be expressed as part of an autoim-
mune polyendocrine syndrome type 2 (APS-2), which is
usually defined by the occurrence of two or more of the
following: Addison's disease (always present), AITD and/
or type 1 diabetes [15], in the same patient.
In common with probably all autoimmune disorders, the
harmful interaction between internal (genetic) and exter-
nal (environmental and endogenous) factors is required
to initiate Hashimoto's disease (Fig. 1). Environmental
triggers of HT include iodine intake [16,17], bacterial and
viral infections [18,19], cytokine therapy [20] and
probably pregnancy [21,22]. The role of dietary iodine is
well defined in epidemiological studies [23,24] and in
animal models [25-27] and seems to be the most signifi-
cant environmental factor to induce thyroiditis.
Possible pathogenic mechanism of Hashimoto's thyroiditis Figure 1
Possible pathogenic mechanism of Hashimoto's thyroiditis. Genetically predisposed individuals could be influenced by an envi-
ronmental trigger (i.e., dietary iodine, infection, pregnancy, cytokine therapy) that induces an autoimmune response against thy-
roid-specific antigens by infiltrating immune cells. The autoimmune process results in preferential T helper type 1 (TH1)-
mediated immune response and induction of apoptosis of thyroid cells that leads to hypothyroidism.Journal of Autoimmune Diseases 2005, 2:1 http://www.jautoimdis.com/content/2/1/1
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Pathogenesis of Hashimoto's thyroiditis
Autoimmunity in Hashimoto's thyroiditis
The development of the autoimmune failure of the thy-
roid is a multistep process, requiring several genetic and
environmental abnormalities to converge before full-
blown disease develops (Fig. 2). At the onset of disease,
major histocompatibility complex (MHC) class II-positive
antigen-presenting cells (APC), particularly dendritic
cells, and different subclasses of macrophages, accumu-
late in the thyroid [28,29]. APC present thyroid-specific
autoantigens to the naïve T cells, leading to activation and
clonal expansion of the latter. Thus, the initial stage of the
disease is followed by a clonal expansion phase and mat-
uration of autoreactive T and B lymphocytes in the drain-
ing lymph nodes.
In autoimmune thyroditis animal models, genetically
determined immune defects have been suggestively
linked to the breakdown of immunological self-tolerance
that results in the presentation of host autoantigens and
expansion of autoreactive lymphocyte clones. These
immune defects are associated with the presence of partic-
ular MHC class II haplotypes, but other immune and
immune regulatory genes (i.e., CTLA-4 and others) are
also involved [30-32].
Breakdown of the immune tolerance might occur in sev-
eral ways including interrupting central tolerance (e.g.
deletion of autoreactive T cells in the thymus), defects in
maintaining peripheral tolerance (e.g. activation-induced
T-cell death and suppressing activity of regulatory T lym-
phocytes) and anergy (e.g. the expression of MHC class II
molecules on non-professional APC). Animal models
genetically predisposed to develop an autoimmune dis-
ease, and patients with AITD, showed a lack of, or a defi-
ciency in, a subpopulation of regulatory T cells with
suppressive function [33-35].
The mechanisms, whereby autoreactive T cells escape
deletion and anergy, and become activated, remain uncer-
tain. There is evidence that the thyroid cell itself, by "aber-
rantly" expressing MHC molecules, can play the role of
"non-professional " APS and present disease-initiating
antigen directly to the T cells [36,37]. The concept of aber-
rant MHC class II expression was supported by studies in
mice. They developed a type of Graves' Disease (GD) after
being injected with fibroblasts coexpressing MHC class II
and the TSH receptor (TSHR). TPO antibody production
was induced after injection with fibroblasts coexpressing
class II molecules and TPO [38,39].
Iodine is a necessary component of normal thyroid hor-
monogenesis. Incorporation of iodine into thyrosine resi-
dues of Tg leads to the formation of mono-iodotyrosine
and di-idothyrosine derivates that subsequently undergo
an oxidative coupling event resulting in the producing of
T3 and T4. Iodine can promote antithyroid immunity in a
number of ways. Several studies suggest that iodination of
Tg is crucial for recognition by Tg-reactive T cells [40,41].
Iodine excess can affect the Tg molecule directly, creating
new epitopes or exposing "cryptic" epitopes. It has been
demonstrated that a highly iodinated thyroglobulin mol-
ecule is a better immunogen than Tg of low iodine content
[41,42]. Therefore, highly iodinated Tg may facilitate anti-
gen uptake and processing by APC. Additionally, high
doses of iodine were shown to directly affect macro-
phages, dendritic cells, B and T lymphocytes, resulting in
stimulation of macrophage myeloperoxidase activity,
acceleration of the maturation of dendritic cells, increas-
ing the number of circulating T cells and stimulating B cell
immunoglobulin production [25]. Excessive amounts of
iodide ion are rapidly oxidized by TPO, thereby generat-
ing excessive amounts of reactive intermediates such as
hypoiodous acid and oxygen radicals. These oxidative spe-
cies damage thyrocyte cell membrane by oxidation of
membrane lipids and proteins causing thyrocyte necrosis
[43]. The state of severe iodine deficiency itself namely
leads to a lowering of thyroid autoimmunity and an
immunodeficient state in autoimmune-prone BB-DP rats.
This hampers the autoreactcive T-cell generation and
autoantibody production [25]. A lower degree of Tg iodi-
nation also makes this molecule less antigenic [42].
An influx of dendritic cells and macrophages to the thy-
roid may occur as a consequence of inflammatory events
in the gland. Early non-specific necrosis of thyrocytes due
to toxins (i.e. iodine, etc.), and perhaps viral or bacterial
infection, can attract these cells to the thyroid. Moreover,
these immune cells are normal constituents of the thyroid
that are able to regulate the growth and function of thyro-
cytes via interleukin-1 (IL-1) and IL-6-mediated pathways
[44].
A central phase of HT is characterized by the recognition
of presented autoantigens by the lymphocytes, followed
by an apparent uncontrolled production of autoreactive
CD4+ T cells, CD8+ cytotoxic T cells and immunoglobu-
lin G (IgG) autoantibodies. Initially, the production of
self-reactive cells and autoantibodies occurs in the drain-
ing lymph nodes (Fig. 2). Later, the lymphoid tissue often
develops directly in the thyroid gland itself. This tissue is
generally very well organized, with cords of anti-Tg-anti-
body-producing plasma cells in the periphery. It is usually
non-destructive and shows a peaceful co-existence with
adjacent thyrocytes.
Thyroglobulin, the main protein synthesized in the thy-
roid, serves both in the synthesis and in the storage of thy-
roid hormones. Human Tg molecules contain at least four
thyroid hormone synthesis sites from the iodinatedJournal of Autoimmune Diseases 2005, 2:1 http://www.jautoimdis.com/content/2/1/1
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A scheme of autoimmune events in Hashimoto's thyroiditis Figure 2
A scheme of autoimmune events in Hashimoto's thyroiditis. In an initial stage, antigen-presenting cells (APC), mostly dendritic 
cell and macrophage (Mφ ) derived, infiltrate the thyroid gland. The infiltration can be induced by an envinromental triggering 
factor (dietary iodine, toxins, virus infection, etc.) which causes insult of thyrocytes and releasing of thyroid-specific proteins. 
These proteins serve as a source of self-antigenic peptides that are presented on the cell surface of APC after processing. Tak-
ing up relevant autoantigens, APC travel from the thyroid to the draining lymph node. A central phase occurs in the draining 
lymph node in which interactions between APC, autoreactive (AR) T cells (that survive as result of dysregulation or breakage 
of immune tolerance) and B cells result in inducing production of thyroid autoantibodies. In the next step, antigen-producing B 
lymphocytes, cytotoxic T cells and macrophages infiltrate and accumulate in the thyroid through expansion of lymphocyte 
clones and propagation of lymphoid tissue within the thyroid gland. This process is preferentially mediated by T helper type 1 
(TH1) cells which secrete regulatory cytokines (interleukin-12, interferon-γ  and tumor necrosis factor-α ). In a final stage, the 
generated autoreactive T cells, B cells and antibodies cause massive depletion of thyrocytes via antibody-dependent, cytokine-
mediated and apoptotic mechanisms of cytotoxity that leads to hypothyroidism and Hashimoto's disease.Journal of Autoimmune Diseases 2005, 2:1 http://www.jautoimdis.com/content/2/1/1
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tyrosine residues at positions 5, 2553, 2567 and 2746
[45]. The hormone synthesis sites and the iodine content
of Tg play an important role in its autoantigenicity [40].
Tg is one of the major autoantigens in thyroid autoimmu-
nity and serologic studies have shown that there are at
least 40 antigenic epitopes on human Tg [16,46]. Tg-anti-
bodies are detected in almost all patients with AITD [47].
Anti-thyroglobulin antibodies were also reported in up to
27% of normal individuals [48]. However, numerous
studies have clearly shown that the epitope recognition
pattern of the natural anti-Tg antibodies is differented
from that of AITD-associated anti-Tg antibodies. Most
studies have demonstrarted a restricted epitope recogni-
tion pattern of AITD subjects by anti-Tg antibodies, in
contrast to polyclonal reactivity observed with anti-Tg
antibodies from healthy individuals [49,50]. Human or
mouse Tg immunization induces experimental autoim-
mune thyroiditis (EAT) in mice [51]. The EAT induction is
HLA-dependent implying an interaction between the Tg
molecule and the MHC glycoproteins [52]. In addition,
alterations to Tg could explain interactions between
genetic and environmental factors in the aetiology of HT.
Thyroid peroxidase is another significant autoantigen in
the thyroid of patients affected with HT and AITD. This
enzyme catalyses the oxidation of iodine to an iodinating
species that forms iodotyrosines in a Tg molecule and sub-
sequently iodotyronines [53]. TPO antibodies are hetero-
geneous. To date, around 180 human TPO anribodies
have been cloned and sequenced. This allows for the pos-
sible identification of major features of the TPO-directed
antibodies repertoire during AITD. In Graves' disease
patients, heavy chain VH domains of anti-TPO antibodies
preferentially use D proximal IGHV1 genes. IGHV3 genes,
mainly located in the middle of the immunoglobulin
heavy chain gene (IGH) cluster on chromosome 15q11,
characterize HT patients more frequently. A large propor-
tion of the anti-TPO heavy chain VH domain comes about
following a VDJ recombination process that uses inverted
D genes [54,55].
Autoantibodies against other thyroid-specific antigens
such as thyrotropin receptor and sodium iodide sym-
porter were also found in serum of HT patients. However,
these antibodies occur at low frequency and do not appear
to contribute any diagnostic power for HT [56,57].
In a final, destructive step of Hashimoto's thyroiditis, the
autoreactive T cells diffusely accumulate in large numbers
and infiltrate thyroid parenchyma (Fig. 2). In the BB-DP
rat model, T-helper type 1 (TH1)-mediated mechanisms
involving production of IL-12, tumor necrosis factor-α
(TNF-α ) and interferon-γ  play a major role in the destruc-
tion of thyrocytes, rather than TH2  type mechanisms
directed by IL-4 and IL-10 [58]. The infiltration of
activated scavenger macrophages into the thyroid folli-
cles, thus destroying the thyroid cells, is compatible with
TH1-mediated mechanisms [59]. Fas and Fas ligand (FasL)
expression was higher in rats with lympholytic thyroiditis
indicating a role of these apoptotic molecules in thyrocyte
death [60].
Apoptosis in Hashimoto's thyroiditis
Autoimmune responses against specific antigens are pri-
mary determinants in thyroid autoimmunity. Other
molecular mechanisms including cell apoptosis may play
a role in determining the opposite phenotypic outcomes
of AITD such as thyroid destruction in HT and thyroid
hyperplasia in GD. T-helper lymphocytes produce
cytokines that influence both immune and target cells at
several levels. The predominance of TH1 or TH2 cytokines
might regulate thyrocyte survival through the induction of
pro-apoptotic and anti-apoptotic proteins. TH1-mediated
mechanisms lead to thyrocyte depletion in Hashimoto's
thyroiditis through the involvement of death receptors
and cytokine-regulated apoptotic pathways [61,62].
The normal thyroid gland has been shown to act as an
immune privileged site having carefully regulated mecha-
nisms of cell death and self-protection against attack by
infiltrating activated T-cells induced by apoptosis [63,64].
Cell apoptosis occurs in the normal thyroid at a low level.
As new thyrocytes are produced, old cells are destroyed in
order to maintain normal thyroid volume and function.
Deregulation of apoptosis, which is weakly determined by
genetic susceptibility, can lead to destructive processes.
Initiation of an out-of-control apoptotic mechanism in
thyroid cells may be caused by various non-genetic inju-
ries that affect expression of apoptosis inhibitor molecule
Bcl-2 or membrane ligand FasL [65]. Thyrocytes from HT
thyroid glands are able to hyperproduce Fas and FasL on
their surfaces thus inducing fratricide apoptosis [66]. IL-
1β , abundantly produced in HT glands, induces Fas
expression in normal thyrocytes, the cross-linking of Fas
resulting in massive thyrocyte apoptosis. This can play a
role in the progression of Hashimoto's thyroiditis [67].
Immune-mediated apoptosis of thyrocytes is directed by
CD8+ cells. Receptors on the target cell are triggered by
lymphocyte ligands and/or released soluble factors are
delivered to the target cell [68]. Receptors involved in
immune-mediated apoptosis include the TNF R1 recep-
tor, the Fas receptor and death receptors DR3 and DR4,
whereas soluble mediators include substances such as per-
forines and TNF [68-70].
The common apoptotic pathway consists of subsequent
activation of specific intracellular proteases known as cas-
pases. These caspases are themselves activated by specific
proteolytic cleavage or may be activated by cleavage per-Journal of Autoimmune Diseases 2005, 2:1 http://www.jautoimdis.com/content/2/1/1
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formed by other caspases. The caspase cascade ultimately
induces enzymes that progressively destroy the cell and its
genetic material, finally lead to cell death. The apoptosis,
or programmed cell death, can be initiated by binding
death ligands, such as TNF, TNF-related apoptosis-
induced ligand (TRAIL) and FasL, to the cell surface. This
in turn starts intracellular signal cascading of caspases
[71].
Several apoptosis signalling pathways, initiated by mole-
cules such as FasL and TRAIL, have been shown to be
active in thyrocytes and may be involved in destructive
thyroiditis [72]. Fas-mediated apoptosis seems to be a
general mechanism of cell destruction in AITD. In GD
patients, reduced levels of Fas/FasL and increased levels of
antiapoptotic molecule Bcl-2 favour thyroid cell survival
and apoptosis of infiltrating lymphocytes. In contrast, the
regulation of Fas/FasL/Bcl-2 expression in HT can pro-
mote thyrocyte apoptosis through homophylic Fas-FasL
interactions and a gradual reduction in thyrocyte numbers
leading to hypothyroidism [61].
Thus, the rate of thyrocyte apoptosis dictates the clinical
outcome of thyroid autoimmunity. Though rare in nor-
mal thyroid, it markedly increases during HT, but not in
GD. Therefore, regulation of thyrocyte survival is a crucial
pathogenic determinant.
Genetics of Hashimoto's thyroiditis
Evidence for genetic susceptibility to Hashimoto's thyroiditis
Abundant epidemiologic data (population-based and
family-based studies, twin studies) suggest a strong
genetic contribution to the development of HT. The dis-
ease clusters in families [22,73]. Thyroid abnormalities
with clinical outcomes were observed in 33% of offspring
of patients with HT or GD [73]. The sibling risk ratio (λ S),
that is the ratio of the prevalence of disease in siblings to
the prevalence in the general population, can be used as a
quantitative measure of the genetic contribution to the
disease. Usually, a λ S of more than five indicate a signifi-
cant genetic contribution to the disease development.
Based on historical data, the λ S for AITD is estimated to be
greater than 10, supporting a strong case of genetic influ-
ence on disease development [74]. Using HT prevalence
data from the NHAHES III study, an estimated λ S value is
about 28 for HT [74].
In Danish twin study, the concordance rates for Hashim-
oto's disease were 38% for monozygotic (MZ) twins and
0 for dizygotic (DZ) twins [75]. For HT, a recent twin
study in California confirmed these results, showing con-
cordance rates of 55% and 0% in MZ and DZ twins,
respectively [76]. For thyroid antibodies, the concordance
rate in the Danish twin study was twice high in MZ twins
(80%) than that in DZ twins [75]. In a recent twin study
in the UK, the concordance rates for Tg-antibodies were
59% and 23% in in MZ and DZ twins, respectively [77].
In this study, the concordance rates for TPO-autoantibod-
ies were 47% and 29% in MZ and DZ twins, respectively
[77]. These data suggest that HT and other AITD outcomes
such as antibody production against thyroid-specific
antigens have a substantial inherited susceptibility. HT
seems to be a polygenic disease with a complex mode of
inheritance. Immunomodulatory genes are expected to
play an important role in predisposing and modulating
the pathogenesis of Hashimoto's thyroiditis.
Animal models of autoimmune thyroiditis
Animal models of AITD still hold immense promise for
the discovery of pathways, genes and environmental fac-
tors that determine the development of thyroid autoim-
munity. Animals affected by experimental autoimmune
thyroiditis (EAT) provide a unique opportunity to
uncover disease-associated pathways, which are compli-
cated to define in man.
One of the oldest inbred models is the obese strain
chicken (OS), which develops goitrous lympholytic thy-
roiditis with the subsequent atrophic lympholytic thy-
roiditis followed by a rapid onset of hypothyroidism [78].
The biobreeding diabetes-prone (BB-DP) rat expresses a
form of focal lympholytic thyroiditis that under normal
conditions does not lead to hypothyroidism [79]. The
nonobese diabetes (NOD) mouse strain NOD-H2h4 spon-
taneously develops iodine-induced autoimmune thy-
roiditis but not diabetes [26]. In particular, this murine
strain has been extensively used to evaluate the role of
iodine in the development of autoimmune thyroiditis
[16].
EAT can be induced in mice by injecting with murine or
human Tg, [80] and in normal syngenic recipients it is
induced by the adoptive transfer of in vitro activated T cells
from Tg-immunized mice [81]. The induced disease is
characterized by the production of murine Tg-specific
antibodies and infiltration of the thyroid by lymphocytes
and other monocytes, with murine or human Tg-specific
CD4+ T cells as the primary effector cells [80,82].
Clinical features of EAT induced in the animal models
mentioned above are similar to those of human HT. For
example, autoimmune thyroiditis in the NOD-H2h4
mouse is induced by dietary iodine that supports epide-
miologic data on human populations. In addition, the
iodinified mouse represents high levels of IgG2b that is
similar to HT patients expressing the predominance of
IgG2 subclass, the human analog of murine IgG2b [83].
IgM class generally restricts Tg-antibodies of normal indi-
viduals and mice, while HT individuals and affected mice
commonly produce Tg-antibodies of the IgG isotype [17].Journal of Autoimmune Diseases 2005, 2:1 http://www.jautoimdis.com/content/2/1/1
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However, anti-TPO antibodies generally detectable in HT
patients could not be found in NOD-H2h4 mice. Despite
some differences between EAT and HT, these animal mod-
els have greatly contributed to the knowledge concerning
the etiology and the pathogenesis of thyroid autoimmu-
nity, most notably on the events occurring in the very
early prodromal phases.
Major Histocompatibility Complex (MHC) molecules are
thought to play an important role in the initial stages of
the development of HT and AITD. MHC molecules, or
Human Leukocyte Antigen (HLA) homologs, play a piv-
otal role in T-cell repertoire selection in the thymus and in
antigen presentation in the periphery. Crystal structures of
MHC molecules show a peptide-binding cleft containing
the variable region of these molecules. Genetic polymor-
phism of the MHC molecule determines the specificity
and affinity of peptide binding and T-cell recognition.
Therefore, polymorphisms within MHC class I and class II
loci can play a significant role in predisposition to
autoimmune disease [84].
A role of selected HLA class II genes susceptible to HT has
been significantly clarified using transgenic NOD (H2Ag7)
class II-knockout mice with EAT as a model for HT
[85,86]. In mouse genome, the H2 class II locus is homol-
ogous to the human HLA class II region [51]. A role for
HLA-DRB1 polymorphism as a determining factor in HT-
susceptibility, with DR3-directed predisposition and DR2-
mediated resistance to the disease, was demonstrated
using H2 class II-negative mice injected with HLA-DRA/
DRB1*0301 (DR3) and HLA-DRB1*1502 (DR2) trans-
genes [85]. A role for HLA-DQ polymorphism was shown
with human thyroglobulin-induced EAT in HLA-
DQ*0301/DQB1*0302 (DQ8), but not HLA-DQ*0103/
DQB1*0601 (DQ6), transgenic mice [52]. In summary,
DR3 and DQ8 alleles are found to be susceptible, whereas
DR2, DR4 and DQ6 alleles are resistant [30,87]. Studies
on EAT-developing mice showed the differential effects of
class II molecules on EAT induction. Susceptibility can be
determined when class II molecules from a single locus,
H2A or HLA-DQ, are examined in transgenic mice, but the
overall effect may depend upon the presence of both class
II molecules H2A and H2E in mice and HLA-DQ and
HLA-DR in humans [88]. Polymorphism within DQ alle-
les can determine predisposition to HT while DRB1 mol-
ecules associated with susceptibility to HT may appear to
play a permissive role. The combination of susceptibility-
inducing HLA-DQ and permissive DR alleles is responsi-
ble for the association of the HLA class II region with the
disease.
T cells recognize an antigenic peptide via interaction of
their membrane T cell receptors (TcR) with antigen-MHC
complexes presented on the surface of APC. Biased or
restricted TcR gene use has been reported in a variety of
human or murine autoimmune diseases [89]. Biased TcR
V gene in intrathyroidal T cells was also observed in mice
with spontatenous (NOD strain) or human Tg-induced
(CBA/J strain) thyroiditis. This confirms the primary role
played by T cells in initiating EAT and the phenomenon of
oligoclonal expansion of intrathyroidal T lymphocytes in
early thyroiditis [90]. Sequencing of amplified TCR V beta
cDNA showed that within each NOD thyroid sample at
least one of the overexpressed V beta gene families was
clonally expanded. For example, in the CBA/J mouse
immunized with human Tg, clonally expressed T cells
were shown to primarily express the murine TcR Vβ 1 and
Vβ 13 sequences [91].
A new murine model that developed destructive thyroidi-
tis with histological and clinical features comparable with
human HT has been recently reported [92]. The transgenic
mice express the TcR of the self-reactive T-cell clone
derived from a patient with autoimmune thyroiditis. The
T-cell clone is specific for the autoantigen thyroid peroxi-
dase (TPO) peptide comprising amino acid residues at
positions 535–551 (TPO535–551) of the TPO amino acid
sequence. This includes a cryptic epitope (TPO536–547)
preferentially displayed after endogenous processing dur-
ing inflammation [93]. These results underline the patho-
genic role of autoreactive human T cells and the potential
significance of recognition of cryptic epitopes in target
molecules such as TPO for inducing thyroid-specific
autoimmune response.
The two-signal theory for T cell activation requires TcR
engagement of its cognate antigen-MHC complex and
CD28 binding to B7 ligands (B7-1 and B7-2) on APC.
Activation of T cells results in increased expression of the
cytotoxic T cell antigen-4 (CTLA-4) molecule that shares
homology with CD28. Although B7-1 (CD80) and B7-2
(CD86) expressed on APC can bind to both CD28 and
CTLA-4 (CD152), because of higher affinity, they prefer-
entially bind to CTLA-4 on activated T cells and attenuate
the T cell response [94].
The importance of CTLA-4 in the down-regulation of T
cell responses and in the induction of anergy and toler-
ance to alloantigens, tumors and pathogens, has been
clearly demonstrated in experiments with CTLA-4 defi-
cient mice. The mice developed a severe inflammatory dis-
order due to up-regulated proliferation of T cells [95,96].
CTLA-4 can down-regulate T cell responses involving
binding and sequestering B7 molecules from CD28,
therefore preventing CD28-mediated co-stimulation.
Another possibility is that CTLA-4 through its intracellular
domain could actively transmit a negative signal resulting
in down-regulation of activated T cells [97]. The crucial
role of CTLA-4 in maintaining self-tolerance breakdownJournal of Autoimmune Diseases 2005, 2:1 http://www.jautoimdis.com/content/2/1/1
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of which leads to the initiatition of a primary autoim-
mune response has been demonstrated in several murine
models of autoimmune diabetes [98] and autoimmune
thyroiditis [32].
Human Leukocyte Antigen class I and II genes
Genes of the human MHC region are clustered on chro-
mosome 6p21 and encode HLA glycoproteins and a
number of additional proteins, which are predominantly
related to immune response. The MHC locus itself con-
tains three groups of genes: class I genes encoding HLA
antigens A, B and C, class II genes encoding HLA-DR, DP
and DQ molecules and class III genes [99].
Previous studies in the early 1980s investigated the HLA
locus in relation to the genetics of HT. Associations
between HLA and HT have both been analysed by sero-
logic typing of HLA and DNA typing using sequence-spe-
cific oligonucleotide probe analysis or restriction
fragment length polymorphism. In Asians, HLA class I
(A2, B16, B35, B46, B51, B54, C3) and HLA class II (DR2,
DR9, DR53, DQ4) genes showed an association with the
disease [31,100-105]. In Caucasians, HT is associated with
HLA class II genes such as DR3, DR4, DR5, DQA1*0301,
DQB1*0201 and DQB1*0301 [106-120] but not with the
HLA-DP and HLA class I (HLA-A, HLA-B and HLA-C)
genes [113,114,121]. However, some studies could not
reveal an association between HLA-DQ and DR genes and
Hashimoto thyroiditis [114,122,123]. Reports of disease-
associated alleles are not consistent, but associations
appear to be strongest with alleles in the HLA-DR and -
DQ loci. This has also been suggested by studies in trans-
genic mouse [30,52,85-87].
Early linkage, non-genome-wide studies of the HLA
region have failed to detect linkage between the HLA locus
and HT [124-129]. Using dataset of 56 US Caucasian mul-
tigenerational families, genome-wide scans has revealed a
susceptibility locus AITD-1 located on chromosome 6p
[130]. The AITD-1 locus is common for both general
forms of thyroid autoimmunity, HT and GD [130]. This
locus was replicated in the expanded dataset of 102 US
Caucasian families but is distinct from the HLA gene clus-
ter [131]. Whole-genome scans of a large family with
members affected with vitiligo and HT mapped a HT sus-
ceptibility locus that shared both the MHC region and the
non-MHC AITD-1 [132]. However, evidence for linkage
between the HLA locus and HT (or autoimmune thyroid
disease) has not been confirmed by further whole-
genome scans of other affected families [133,134], sibling
pairs [135], or within HLA-DR3 positive families [120].
The lack of linkage means, for instance, the DR3 gene did
not cause the familial segregation of Hashimoto's disease
while a relatively strong and consistent association
showed that HLA-DR3 conferred a generalized increased
risk of HT in the general population. These data did not
support a major role for the HLA region in the susceptibil-
ity to HT and may imply that the DR3 gene modulates the
effect of other non-HLA susceptibility gene.
However, a linkage between the HLA region and HT was
recently shown in the data set of 40 US multiplex families
affected with AITD and type 1 diabetes [136]. The linkage
to HT was found to be weaker than to diabetes, suggesting
that additional, non-HLA loci were contributing to the
joint susceptibility to AITD and T1D. Among HLA-DR
alleles, HLA-DR3 was detected as the only associated gene
for Hashimoto's thyroiditis and diabetes [136]. Indeed,
DR3 seems to represent the major HLA allele, which con-
tributes to the shared susceptibility to T1D and AITD.
These findings, however, need to be replicated in larger
data sets because early family [137,138] and case-control
[139,140] studies have not shown the unique role for
HLA-DR3 allele in conferring shared susceptibility to T1D
and thyroid autoimmunity.
The HLA region has been established to be involved in
multiple autoimmune disorders [141]. The mechanisms
by which HLA molecules influence the susceptibility to
autoimmune disorders become more and more clear. Dif-
ferent HLA alleles could have different affinities to
autoantigenic peptides. Therefore, certain alleles can bind
the autoantigenic peptide, with the subsequent recogni-
tion by T cells that have escaped self-tolerance, whereas
others may not [142]. The possibility of certain class II
alleles to bind and present thyroid-specific antigens such
as TSHR or Tg peptides has been shown in vitro [143] and
in mice with EAT [144].
Thyroid autoantigens need to occur in the thyroid or its
draining lymph nodes in order for them to be presented
by HLA molecules. It has been suggested that an aberrant
intrathyroidal expression of MHC class II molecules by
thyrocytes is necessary to initiate thyroid autoimmunity
[145,146]. This hypothesis is supported by detection of
the expression of HLA class II molecules by thyroid epi-
thelial cells in HT and GD patients [147,148] and in stud-
ies on animal models with experimentally induced
thyroid autoimmunity [85,145,149,150]. The aberrant
expression of HLA class II antigen by thyrocytes can initi-
ate autoimmune responses through direct thyroid self-
antigen presentation or a secondary event following on
from cytokine secretion by infiltrated T lymphocytes
[148,151].
Genetic contribution of HLA varies depending on the dis-
ease. HLA involvement in T1D, rheumatoid arthritis or
multiple sclerosis is large and can constitute more than
50% of the genetic risk [84,152]. Contributions of HLA
alleles as genetic risk factors to HT are much weakerJournal of Autoimmune Diseases 2005, 2:1 http://www.jautoimdis.com/content/2/1/1
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[118,153]. HLA class I and II genes appear to contribute to
the autoimmunity in general but not to organ specificity.
Their role in the predisposition to HT is rather non-spe-
cific [62,117]. The HLA class I and II genes appear not to
be the primary HT genes, and are likely to be modulating
genes that increase the risk for AITD contribution by other
genes. HLA class III and other non-HLA genes, located in
the HLA region, are also critical to the immune response.
It is possible that HLA associations as seen in thyroid
autoimmunity are due partially to genetic variation in
these closely linked immune regulatory genes and their
linkage disequilibrium with class I and II genes [154].
HLA class III genes and non-HLA genes of the HLA region
The HLA class III region lies between class I and II genes
and encodes important immunoregulatory proteins such
as cytokines [tumour necrosis factor (TNF), lymphotoxin
alpha (LT-α ) and beta (LT-β )], complement components
(C2, C4, properdin factor B) and heat shock proteins
(HSP) [155]. Both TNF and LT-α  mediate B-cell prolifera-
tion and humoral immune responses [154]. TNF has been
found to enhance cellular expression of HLA class I and II
antigens, and enhances adhesion and complement regula-
tory molecules in the thyroid gland of HT patients. Alter-
ations to the above could promote the autoimmune
process [156]. However, case-control studies showed no
association between polymorphisms within the TNF and
LT-α  genes and HT in Germans [112], UK Caucasians
[118] and Koreans [157].
HSP70 gene cluster consists of three genes encoding
HSP70-1, HSP70-2 and HSP-Hom proteins. They are
expressed in response to heat shock and a variety of other
stress stimuli (e.g. oxidative free radicals, toxic metal ions
and metabolic stress). HSPs are also important for antigen
processing and presentation [158]. Genetic variations
within all three HSP70 genes were tested in British
patients with HT and no associations were found [118].
Polymorphisms of complement component-encoding
genes have not yet been evaluated in relation to HT.
Meanwhile, finding a link between frequency distur-
bances in BI and C4A allotypes and one of the forms of
thyroid autoimmunity, postpartum thyroiditis [159], may
be an intriguing future study in HT patients.
Other genes crucial to the immune response, including
TAP (transporters associated with antigen processing),
LMP (large multifunctional protease), DMA and DMB
genes are located within the HLA class II region [155].
Protein products of TAP (TAP1 and TAP2) and LMP2
(LMP2 and LMP7) genes participate in the proteolysis of
endogenous cytoplasmic proteins into small fragments
and subsequent transportation of these self-peptides from
the cytoplasm into the endoplasmic reticulum, the site of
HLA class I assembly [160]. To date, one investigation has
been concerned with the association between TAP1 and
TAP2 genes and Hashimoto's thyroiditis. No significant
association was observed in the British population [118].
The genetic role of LMP in HT has not yet been examined.
An association between the R60 allele of the LMP2 gene
and GD was observed [161]. Additionally, quantitative
defects in the amount of transcription products of TAP1,
TAP2, LMP2 and LMP7 genes were found in lymphocytes
of patients with AITD [160]. These findings suggest that
defective transcription of HLA class I-processing genes
could contribute to the quantitative defect in cell-surface
expression in autoimmune lymphocytes in HT. Further
evaluation of the role of such class I-processing genes as
TAP and LMP is necessary.
DMA and DMB genes are involved in the assembly of HLA
class II peptides. These genes encode subunits of a func-
tional heterodimer that is critical for class II antigen pres-
entation [160,162]. Based on nucleotide variation within
exon 3, three rare DMB alleles (DMB*01kv1, DMB*01kv2
and DMB*01kv3) have been detected in Korean HT
patients while these DMB variants have not been found in
healthy subjects [163]. However, these DMB alleles have
not yet been functionally characterized. In summary,
there is a significant dearth of information on how HLA
class III genes and non-HLA genes, located in the HLA
region, contribute to the pathogenesis of HT. Further stud-
ies are required to clarify the involvement of these genes
in HT susceptibility.
CTLA-4 gene
The CTLA-4 gene is the most frequently studied of the
immune modulatory genes located outside the HLA
region, in relation to the genetics of HT. This gene encodes
a costimulatory molecule, which suppresses T-mediated
immune response and is crucial in the maintenance of
peripheral immunological self-tolerance [164]. An inven-
tory of case-control studies based on the association
between three polymorphic markers within the CTLA-4
gene [A49G dimorphism in the leader peptide, C (-318) T
substitution in the promoter region and a dinucleotide
repeat polymorphism at the 3'-untranslated region (3'-
UTR)] and HT is reviewed in [165]. Results of these stud-
ies, except for those for the C (-318) T single nucleotide
polymorphism, suggest that polymorphisms within the
CTLA-4 gene are associated with the development of HT.
Family studies showed linkage between CTLA-4 and GD
[166], thyroid antibody production [167] and autoim-
mune thyroid disease [12,62] but not specifically to HT,
probably due to lack of their power [129,130,135]. Clas-
sical linkage analysis is suitable for detecting susceptibility
loci with major genetic effects. CTLA-4 demonstrates a
modest but significant effect in the genetics of HT. ToJournal of Autoimmune Diseases 2005, 2:1 http://www.jautoimdis.com/content/2/1/1
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detect a locus with a modest genetic effect, a large number
(at least 400) of affected families should be tested [168].
This investigation has recently been performed involving
about 600 AITD families and more than 1300 affected
patients [169]. The CTLA-4 gene has been found to play a
critical role in the pathogenesis of autoimmune diseases
such as GD, HT and T1D [62,153,169]. Disease suscepti-
bility was mapped in the 6.1-kb 3' untranslating region of
CTLA-4. Allelic variation was correlated to altered mRNA
levels of soluble form of CTLA-4 [169]. This alternative
splice form of CTLA-4 lacks exon 3 encoding the trans-
membrane domain but maintains exon 2 encoding the
ligand-binding domain [170]. The short form of CTLA-4
can bind CD80/86 and inhibit T-cell proliferation [171].
The soluble CTLA-4 (sCTLA-4) is expressed constitutively
by T regulatory cells suppressing the effector T-cell
response [172]. Its role in autoimmune disease is not
exactly clear, but sCTLA-4 was observed significantly more
often in patients with AITD [173] and myasthenia gravis
[174] in comparison with non-affected subjects. Patients
with AITD and myasthenia gravis had an aberrant expres-
sion of the CTLA-4 products, with high levels of sCTLA-4
and low levels of the intracellular form [175]. Soluble
CTLA-4 might play an important role in immune regula-
tion by binding with the B7 molecules, thus interfering
with the binding of CD28 and/or full-length CTLA-4.
Interference of sCTLA-4 with B7/CTLA-4 interactions
could block suppressive signals transferred via surface-
bound CTLA-4. Therefore, high concentrations of sCTLA-
4 in serum might contribute to disease manifestations
through interference of sCTLA-4 with B7/CTLA-4
interaction.
It may be that the amino acid change at codon 17 of the
signal peptide could alter the function of the signal pep-
tide to direct intracellulat trafficking of CTLA-4. In in vitro
expreriments, the Ala17 (G49) allele was found to repre-
sent a translation product, which was not glycosylated in
one of two N-linked glycosylation sites [176]. This aber-
rantly glycosylated product was shown to be further trans-
located from the endoplasmic reticulum back to
cytoplasm and, probably, to become a target for proteo-
lytic degradation. In addition, the distribution of Ala17
CTLA-4 variant on the surface of COS1 cells is signifi-
cantly less density than the Thr17 variant of CTLA-4 [176].
These fundings suggest that the Ala17 allele is linked to
the inefficient glycosylation of CTLA-4, which subse-
quently could affect suppressing effects of the CTLA-4
molecule. This could also explain observations showing
that the G49 allele of the CTLA-4 signal peptide is associ-
ated with accelerated proliferation of T lymphocytes in
human subjects homozygous for this allele, and with sup-
pression of the downregulation of T-cell activation in
response to IL-2 [177,178].
The codon 17 single nucleotide polymorphism (SNP) is
shown to be in tight linkage disequilibrium with another
SNP situated at position (-318) of the CTLA-4 promoter
region and with the (AT)n repeat polymorphism at the 3'-
UTR of the CTLA-4 gene [176,179-181]. For the C (-318)
T SNP, the protective T (-318) allele demonstrated higher
promoter activity than the alternative C allele in a luci-
ferase expression assay [182]. Since the (-318) dimor-
phism occurs in a potential regulatory region, this suggets
that this nucleotide substitution may influence the expres-
sion of CTLA-4. However, this possibility remains to be
explored.
The (AT)n repeat polymorphism at the 3'-UTR of the
CTLA-4 gene has been shown to affect the expression of
this costimulatory molecule [174]. Adenylate- and uri-
dylate-rich elements (AUREs) presented in the 3'-UTRs
can regulate stability of eukaryotic mRNAs, and their pres-
ence correlates with rapid RNA turnover and translational
and posttranslational control [183,184]. The AT repeats in
the 3'-UTR of CTLA-4 might represent a special type of of
A U R E s .  C T L A - 4  m R N A  w i t h  l o n g e r  ( A T ) n alleles have
shorter half-lives and, hence, are more unstable
[174,185]. Indeed, the (AT)n microsatellite in the 3'-UTR
influences the mRNA stability. Additionally, the CTLA-4
AT-repeat polymorphism was recently shown to alter the
inhibitory function of CTLA-4. The long AT-repeat allele is
associated with reduced control of T-cell proliferation and
thus contributes to the pathogenesis of GD [186].
The AT-repeat may also affect splicing of one or more of
the alternative CTLA-4 transcripts but this should be clar-
ified. Ueda et al. [169] showed that another polymor-
phism (A6230G, or CT60 SNP) located in the first
position of the 3'-UTR correlates with higher expression of
a soluble CTLA-4. In this study, the highest power of link-
age with GD was found for this SNP and three other SNPs
(JO27, JO30 and JO31) within a 6.1-kb segment of the 3'-
UTR, but not for the (AT)n repeat polymorphism [169].
However, no T-cell function data were presented. Thus,
further investigations are necessary to evaluate functional
significance of these SNPs. Due to the linkage disequilib-
rium, it is currently not possible to determine whether
one, or both, are of physiological importance. It can not
be excluded that allele combination of several closely
linked CTLA-4 polymorphisms might form a functionally
significant haplotype that is directly involved in the sus-
ceptibility to autoimmune disease [187,188].
It should be noted that the genomic region 2q33 linked to
autoimmune disease contains cluster of three genes
encoding costimulatory molecules CTLA-4, CD28 and
inducible costimulator (ICOS) [189]. However, genetic
studies showed that the AITD gene in the 2q33 locus is theJournal of Autoimmune Diseases 2005, 2:1 http://www.jautoimdis.com/content/2/1/1
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CTLA-4 gene and not the CD28 or ICOS genes
[167,169,181].
The CTLA4 gene should be recognised as the first major
known non-HLA locus of human autoimmunity and that
its role in the pathogenesis of HT is rather general and
non-specific [74,153]. Association of CTLA-4 with the
production of thyroid antibodies [167,190], an event that
often represents the subclinical stage of AITD [1], can
explain non-specific mechanism of CTLA-4-mediated sus-
ceptibility to the development of thyroid autoimmunity.
The association of the CTLA-4 gene with several autoim-
mune diseases such as T1D [153,169], Addison's disease
[191,192], multiple sclerosis [193,194], myasthenia
gravis [175] and all clinical outcomes of AITD [74], can
also explain the general contribution of CTLA-4 to
autoimmunity. Interestingly, AITD, Addison's disease and
autoimmune diabetes frequently coexist in patients with
the autoimmune polyendocrine syndrome type II as men-
tioned above. The above disorders seem to share a genetic
background, and CTLA-4 could represent a common sus-
ceptibility focus for them [195]
Other immune regulatory genes
In initial phases of AITD, oligoclonal expansion of T lym-
phocytes occurs in the thyroid gland. These T cells are
restricted by their T cell receptor V gene use [89,90]. There-
fore, the TcR may be considered a likely candidate gene for
AITD and HT. Early case-control investigations showed a
lack of association between HT and the T-cell receptor-α
gene in the US white population [111] but not the T-cell
receptor-β  gene in the Japanese [102]. Linkage analysis
using a US Caucasian AITD family dataset [129] and Tuni-
sian affected pedigree [196] has eliminated the T-cell
receptor V alpha and V beta gene complexes, located on
14q11 and 7q35, respectively, as candidate genes for sus-
ceptibility to thyroid autoimmunity. Therefore, the TcR
genes are not major susceptibility genes for HT and AITD.
Another likely candidate among immune-related genes
was the IGH gene because HT individuals commonly pro-
duce Tg-autoantibodies restricted by IgG class [50]. Early
investigations found an association between IgH Gm allo-
types and AITD in the Japanese [197,198]. However, these
findings have not been confirmed in Caucasians
[129,196].
Cytokines are crucial in the regulation of immune and
inflammatory responses. Multiple investigations showed
the important role of these regulatory molecules in direct-
ing autoimmune and apoptotic pathogenic processes, of
particular, in central and late stages of the development of
HT [72,80,199]. Therefore, cytokine genes might be good
candidates for HT. Intrathyroidal inflammatory cells and
thyroid follicular cells produce a variety of cytokines,
including interleukin-1α  (IL-1α ), IL-1β , IL-2, IL-4, IL-6,
IL-8, IL-10, IL-12, IL-13, IL-14, tumor necrosis factor-α ,
and interferon-γ  [200]. Hunt et al. [201] evaluated 15 pol-
ymorphisms within nine cytokine genes for IL-1α , IL-1β ,
IL-1 receptor antagonist (IL1RN), IL-1 receptor 1, IL-4, IL-
4 receptor, IL-6, IL-10, and transforming growth factor-β
in British patients with AITD. They only found a signifi-
cant association for one of those. The T-allele of the IL-4
promoter [T (-590) C] polymorphism was associated with
lower risk of GD and AITD but not HT [201]. Blakemore
et al. [202] failed to find an association between a poly-
morphic minisatellite in the IL1RN gene and HT in
another group of affected patients from UK. Thus, it may
be concluded that these genes are not major susceptibility
genes for thyroid autoimmunity but need to be further
studied.
The autoimmune regulator (AIRE1) gene is known to con-
tribute to the pathogenesis of autoimmune polyendocrin-
opathy-candidiasis-ectodermal dystrophy (APECED), a
rare monogenic autoimmune disease with endocrine
components including T1D, adrenal failure, and thyroid
dysfunction, with major autoantibodies directed against
adrenal, pancreas, and thyroid tissue [203]. However,
studies in UK patients showed no relation between a 13-
bp deletion at nucleotide 964 in exon 8 (964del13) of the
AIRE1 gene, a common disease-associated marker for
APECED in British population, and HT [204].
The vitamin D-mediated endocrine system plays a role in
the regulation of calcium homeostasis, cell proliferation
and (auto) immunity. 1,25-Dihydroxi-vitamin D3
(1,25(OH)2D3) is the most active natural vitamin D
metabolite that effectively prevents the development of
autoimmune thyroiditis in an animal model [205] and
inhibits HLA class II expression on endocrine cells [206].
C/T polymorphism located at intron 6 of the vitamin D
1α -hydroxylase (CYP1α ) gene failed to show association
with HT in Germans [207]. Two polymorphic markers
within the vitamin D-binding protein gene encoding
another member of the vitamin D metabolic pathway also
showed no association with HT in the German popula-
tion [208]. However, among two polymorphic sites tested
at the vitamin D receptor (VDR) gene, the Fok I(+) allele
of the FokI/restriction fragment length polymorphism
was found to be associated with higher risk HT in Japa-
nese females [209]. Meanwhile, the VDR gene remains to
be a likely candidate for the common autoimmune sus-
ceptibility gene because it has been found to be associated
with autoimmune disorders such as GD [210], Addison's
disease [211], multiple sclerosis [212] and T1D [213].
Thus, a wide variety of non-HLA immune regulatory genes
located outside the HLA region showed no significant
linkage or association with HT and AITD except for theJournal of Autoimmune Diseases 2005, 2:1 http://www.jautoimdis.com/content/2/1/1
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CTLA4 gene. However, we still cannot estimate whether or
not these genes significantly contribute to HT susceptibil-
ity due to a serious shortfall in information about their
role in this disorder. It cannot be excluded that other
genes in linkage disequilibrium with these genes are the
susceptibility genes at these loci.
Thyroid-specific genes
Antibodies against thyroid peroxidase are one of the most
specific features of HT [214]. Therefore, the TPO gene is
expected to be a putative candidate responsible not only
for susceptibility to HT but also for specific determination
between two common outcomes of AITD, such as HT and
GD. Genetic transmission of the recognition by antibody
of the TPO immunodominant region and the TPO B
domain has been described in families affected with HT
[215]. This transmission could be explained by genetic
variations within the TPO gene. However, case-control
studies showed lack of association between the TPO gene
polymorphisms and AITD [113,216]. These data suggest
that the thyroid peroxidase gene does not play an impor-
tant role in predisposition to HT. Subsequent studies are
necessary to clarify exactly whether this gene is a true sus-
ceptibility gene for AITD.
Within the other thyroid-specific gene, the TSHR gene, the
T52P amino acid substitute was examined in US white
and Thai populations but no association with HT was
found [217,218]. Various genome-wide scans have failed
to detect linkage between the thyrotropin receptor gene
and HT or AITD [130,133-135,219,220]. However, two
microsatellites, an (AT)n marker at intron 2 of the TSHR
gene and a (CA)n marker that was mapped to approxi-
mately 600 kb of the TSHR gene, have been shown to be
strongly associated with HT in Japanese patients
[221,222]. The TSHR gene, therefore, does not seem to be
a major susceptibility gene for HT, although a minor role
cannot be excluded.
Tg-specific autoantibodies are common in AITD. The thy-
roglobulin gene makes a significant contribution to HT
and AITD. Whole-genome scans in Japanese-affected sib-
ling pairs have detected a HT susceptibility locus on chro-
mosome 8q24, with a maximum linkage to marker
D8S272 [135]. This marker is separated by 4.6 megabases
(Mb) from the Tg gene. Subsequent studies of the mixed
US and European Caucasian family dataset has confirmed
the susceptibility locus to be on chromosome 8q24, with
the maximum linkage to markers D8S514 and D8S284
[74,131,223]. These markers border a large region of chro-
mosome 8 spanning about 15 Mb. The thyroglobulin
gene is located within this region. Moreover, a new micro-
satellite marker Tgms2 inside intron 27 of the Tg gene
showed strong evidence of linkage and association with
AITD [223,224]. Two new microsatellites have recently
been described in introns 29 and 30 of the thyroglobulin
gene that can be useful for further linkage studies in fam-
ilies with autoimmune thyroid diseases [225]. Using a
high-density panel of SNPs within the human and murine
Tg genes, Ban et al. [226] identified a unique SNP haplo-
type, consisting of an exon 10–12 SNP cluster in both
genes and, additionally, exon 33 SNP in the human gene,
associated with AITD in humans and with EAT in mice.
Taken together, these data strongly suggest that the thy-
roglobulin gene could represent the susceptibility gene for
HT and AITD on 8q24 [74,227] and, therefore, be charac-
terized as the first thyroid-specific susceptibility gene for
thyroid autoimmunity [228].
The Tg gene spanning over 300 kilobases long is expected
to harbour more than one haplotype block associated
with AITD since the length of a linkage disequilibrium
block of SNPs is shown to be less than 100 kilobases
[229]. It seems that this gene is AITD-specific but is not a
HT-specific susceptibility gene. The manner in which the
Tg gene can be a predisposition to AITD remains unclear.
It could be that amino acid variations within the Tg gene
can affect the immunogenicity of Tg. The evidence that
iodination of thyroglobulin affects its immunogenicity
favours this suggestion [230,231]. However, additional
studies are required to evaluate that.
Recent investigation in Tunisians showed significant asso-
ciation of two polymorphic microsatellites (D7S496 and
D7S2459) close to the PDS gene (7q31) with GD and HT,
and one of them, D7S496, was linked to GD only [232].
The PDS gene encodes a transmembrane protein known
as pendrin. Pendrin is a chloride/iodide transporting pro-
tein identified in the apical membrane of the thyroid
gland [233]. Data of Kacem et al. [232] suggest that the
PDS gene might be considered a new susceptibility gene
to autoimmune thyroid diseases, having a different
involvement with different diseases. However, studies in
other populations are necessary to support a role for the
PDS gene in thyroid autoimmunity and HT.
Finally, a role for other genes specifically expressed in the
thyroid gland, has yet to be defined. These genes include
those encoding thyrotropin-β , thyroid-specific factor-1,
sodium iodide (Na+/I) symporter and paired box tran-
scription factor-8, among others. They also need to be
evaluated for any putative impact on HT.
Apoptotosis-related genes
Two polymorphic sites within the FasL gene were recently
tested in HT Caucasian patients from Italy and Germany.
No association between these polymorphisms and the
disorder was shown [234]. Assuming a lack of association
of the naturally occurring FasL gene polymorphisms with
multiple other autoimmune diseases tested, we concludeJournal of Autoimmune Diseases 2005, 2:1 http://www.jautoimdis.com/content/2/1/1
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that genetic variation within this gene does not contribute
to autoimmunity. Inactivating mutations within the Fas
and FasL genes are associated with carcinogenesis
[235,236]. This situation is common among apoptotic-
related genes encoding caspases, death receptors, decoy
receptors and death ligands as well as for genes that
encode other types of signalling molecules [237].
However, since apoptotic mechanisms play a critical role
in pathogenesis and progression of HT, genes associated
with programming cell death should be evaluated
whether or not they confer susceptibility to HT.
Other genes
Due to the prevalence of thyroid autoimmunity in
females, gender-related genes could also be considered as
putative candidates for HT susceptibility. Some of these
genes, such as the CYP19 gene encoding aromatase that
participates in estrogen synthesis, and genes for estrogen
receptor-α  (ESR1) and -β  (ESR2), were examined but
showed no linkage with HT [238]. The ESR1 and ESR2
genes demonstrated no association with AITD in the Jap-
anese [239,240]. It seems that the CYP19 and both estro-
gen receptor genes do not predispose to HT and AITD.
Other gender-specific genes could contribute to AITD. A
possible involvement of such genes has been shown for
GD with the discovery of a susceptible locus on chromo-
some X [238].
The SEL1L gene, encoding a novel transcription factor,
was recently described [241]. The gene is located on chro-
mosome 14q24.3-q31 close to the GD-1 susceptibility
locus [128,130,219] and considered a likely candidate for
thyroid autoimmunity. However, a case-control study in
the Japanese population detected no association of a
dinucleotide (CA)n repeat polymorphism in the intron 20
of the SEL1L gene with AITD [242]. This gene may be a
potentially predisposing gene to T1D because it is specifi-
cally expressed in adult pancreas and islets of Langerhans
[241]. It lies in the vicinity to IDDM11, a susceptibility
locus to this autoimmune disease, on chromosome
14q24.3-q31 [243].
A new zink-finger gene designated ZFAT (a novel zink-fin-
ger gene in AITD susceptibility region) has been recently
found on chromosome 8q24 [244]. The T allele of the
Ex9b-SNP10 dimorphism representing an adenine-to-thy-
midine substitution within intron 9 of this gene was
shown to be associated with high risk for AITD in Japa-
nese patients. Functional studies showed that the Ex9b-
SNP10 significantly affects the expression of the small
antisense transcipt of ZFAT (SAS-ZFAT) in vitro and this
expression results in the decreasing expression of the trun-
cated form of ZFAT (TR-ZFAT) [244]. This SNP is located
in the 3'-UTR of TR-ZFAT and in the promoter region of
SAS-ZFAT. Full-length ZFAT and TR-ZFAT encode a
protein with unknown function, which has eighteen and
eleven repeats of zink-finger domains, respectively. Both
molecular variants of ZFAT are expressed in different tis-
sues including peripheral blood lymphocytes, while SAS-
ZFAT is exclusively expressed in peripheral blood B cells
and represents a non-coding RNA with putative regulatory
function [245]. The disease-associated polymorphism can
play a significant role in B cell function by enfluencing the
expression level of TR-ZFAT through regulation of tran-
scription of SAS-ZFAT. Interestingly, Shirasawa et al.
found no association of the thyroglobulin gene with AITD
when studying different ethnic groups [244]. These results
suggest that the ZFAT gene could implicate the suscepti-
bilty to AITD on chromosome 8q24 but that it needs to be
strongly replicated in other populations. Additionally, the
ZFAT gene should be functionally studied to clarify
whether the ZFAT or thyroglobulin gene are true contrib-
utors of genetic susceptibility to AITD and HT on 8q24.
Non-defined susceptibility loci for Hashimoto's thyroiditis and 
autoimmune thyroid disease
At present, the CTLA-4 (chromosome 2q33), thyroglobu-
lin (or ZFAT) (8q24) and likely HLA genes (6p21.3) are
the only susceptibility loci for HT and thyroid autoimmu-
nity to be mapped. Two HT-specific susceptibility loci that
have been detected in mixed Caucasian families from USA
and Europe, HT-1 (13q) near marker D13S173 and HT-2
on chromosome 12q in the vicinity of marker D12S351,
are still not defined [130]. HT-2 locus has been subse-
quently replicated in the extended dataset, with a peak
linkage close to marker D12S346, which HT-1 does not
have [223]. Possible candidate genes for susceptibility to
HT positioned within the HT-2 locus may include the
BTG1 and CRADD genes. The BTG1 gene encodes B-cell
translocation protein-1, which play an immune regula-
tory role as a negative regulator of the proliferation of B
cells [246]. The GRADD gene encodes CASP-2 and RIPK-
domain-containing adaptor with death domain, that rep-
resents apoptotic function, inducing cell apoptosis via
recruiting caspase 2/ICH1, TNF receptor 1, RIPK-RIP
kinase and other proteins [247].
AITD-1 locus located on chromosome 6p is very close yet
distinct from the HLA region [120,130]. It has been
shown that the AITD-1 is positioned in the same location
as susceptibility loci for T1D (locus IDDM15) [248] and
systemic lupus erythematosus [249]. This may imply that
a general autoimmunity susceptibility gene is located in
this region. The AITD-1 locus contains an interesting posi-
tional candidate gene such the SOX-4 gene, encoding a
transcription factor that modulates differentiation of lym-
phocytes [250].
A whole-genome scan in Japanese showed evidence for
linkage with AITD on chromosome 5q31-q33 [135,251].Journal of Autoimmune Diseases 2005, 2:1 http://www.jautoimdis.com/content/2/1/1
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The 5q31 locus was replicated by recent genome-wide
scan in Caucasian population, the Old Order Amish of
Lancaster County, from Pennsylvania [220]. This locus
harbours a cluster of cytokine genes and, therefore, several
positional candidate genes occur in this region and need
to be evaluated.
In the Chinese, a whole-genome screening for AITD sus-
ceptibility found two chromosome regions (9q13 and
11q12) linked to AITD [134]. Susceptibility genes have
yet to be defined within these regions. However, the 9q13
locus harbours a putative candidate gene such as the
ANXA1 gene, whose product annexin A1 prevents the pro-
duction of inflammatory mediators [252]. The 11q12
locus contains several interesting candidate genes encod-
ing immune modulators (CD5 and CD6) and possible
components of antigenic peptide processing (PSMC3)
and transport (PTH2).
In a large Tunisian family affected with AITD, a suscepti-
bility locus was mapped on 2p24 [133] This locus harbors
two possible candidate genes such as the FKBP1B gene,
product of which demonstrates immune modulating
activity [253], and the TP53I3 gene encoding p53-induci-
ble protein 3 that is involved in p53-mediated apoptotic
pathway [254].
These data suggest that both HT and AITD show genetic
heterogeneity in different populations. Susceptibility loci
differ in their chromosome location depending on the
population being tested. The contributory value of these
genes to the disease pathology varies significantly depend-
ing on the ethnic background. A gene, that has a major
effect on the susceptibility to HT in one population, may
contribute weakly in other population. To date, several
regions of linkage to HT and AITD have been defined. Fur-
ther studies are required to find a true susceptibility gene
in these genomic regions to reveal the functional signifi-
cance of disease-associated polymorphisms within these
genes.
Conclusion
AITD can be initiated in individuals genetically predis-
posed to AITD by non-genetic (environmental) triggers
such as dietary iodine, infection, pregnancy, cytokine
therapy (Fig. 1). This interaction leads to different clinical
phenotypes of thyroid autoimmunity such as Graves' dis-
ease, Hashimoto's thyroiditis or production of thyroid
antibodies. HT and GD are two distinct but related clinical
outcomes of AITD. It seems that both thyroid diseases
have common pathogenic mechanisms as their initial
steps including breakdown of the immune tolerance and
accumulation of T lymphocytes in the thyroid gland.
Sequence variants of CTLA-4, associated with increased
levels of the soluble form of this immune costimulator
and with stability of CTLA-4 mRNA, could play a crucial
role in the earliest stages of AITD (i. e. breakdown of self-
tolerance and surviving autoreactive T lymphocytes). This
role might be sufficient to regulate subsequent steps in the
development of autoimmune responses to the production
of thyroid autoantobodies [167].
Environmental factors (particularly, iodine intake and
infection) could cause insult of the thyrocyte followed by
abnormal expression of MHC class I and class II mole-
cules, as well as changes to genes or gene products (such
as MHC class III and costimulatory molecules) needed for
the thyrocyte to become an APC [255]. In this stage, a
modulating role of sequence variants of HLA class II mol-
ecules could become pivotal in binding and presenting
thyroid antigenic peptides derived from Tg, TPO and
TSHR. Genetic variations in Tg, and probably in TSHR and
other thyroid-specific genes, might be responsible for gen-
erating an autoimmune response.
In later stages, thyroid autoimmunity could be switched
towards GD or HT. GD is characterized by TH2-mediated
switching of thyroid-infiltrating T cells. These induce the
production of stimulating anti-TSHR antibodies by B cells
and anti-apoptotic mechanisms that lead to clinical
hyperthyroidism. In HT, preferential TH1 response initi-
ates apoptosis of thyroid cells and results in clinical
hypothyroidism [22].
It is clear that a number of loci and genes determine
genetic predisposition to HT, with varying effects. These
loci could be unique to HT or general for both HT and
GD. Several whole-genome scans showed results suggest-
ing that there is significant shared susceptibility to HT and
GD [130,131,134,135]. This is also supported by the fre-
quent coexistance of both diseases in affected families
[74,133]. Preliminary data suggest that shared genetic sus-
ceptibility involves both immune regulatory (i. e. CTLA-4
and HLA) and thyroid-specific genes (i.e. Tg). These genes
are not responsible for the determination of pathogenic
mechanisms of thyroid autoimmunity distinct for HT and
GD. It remains unclear which susceptibility genes are spe-
cifically involved in the HT pathogenesis.
The CD40 gene, an important immune modulator,
appears to act as a GD-specific susceptibility gene. The
gene is located within the 20q11 locus and shows signifi-
cant linkage to GD, but not to HT, in UK Caucasians
[74,130,131,256,257]. Subsequent analysis found the
CD40 gene to be associated with GD [258]. However, this
finding needs to be independently confirmed in other
population samples.Journal of Autoimmune Diseases 2005, 2:1 http://www.jautoimdis.com/content/2/1/1
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A probable susceptibility gene that could direct switching
towards GD or HT is thought to be located within the
5q31 locus, which is linked to AITD and contains a
cytokine gene cluster. Different sets of cytokines are
known to regulate switching to TH1 or TH2 type mecha-
nisms [58]. There may be two susceptibility genes, each of
which uniquely contributes to the development of HT- or
GD-specific pathogenesis. The IL-4 promoter [T(-590) C]
polymorphism also appears to be associated with GD, but
not with HT [199]. IL-4 mediates TH2 type mechanism,
which can lead to hyperthyroidism [259].
Another HT-specific susceptibility gene(s) may be an
apoptotic gene. Apoptosis of thyroid follicular cells is the
hallmark of HT and might be the primary cause of death
of thyrocytes compared to T cell-mediated cytotoxity [69].
Thus, it is necessary to identify additional susceptibility
genes and disease-associated polymorphisms in apoptotic
genes in AITD- and HT-linked loci by using a fine map-
ping approach and high-density panels of SNPs. Further
functional analysis and search for correlations between
genotype and phenotype will help to evaluate the role of
these genes in the development of autoimmune thyroid
disease. Susceptibility genes interact with thyroid autoim-
munity [62,130], and the level of these interactions could
affect disease severity and clinical expressions. The molec-
ular mechanisms of these interactions is unknown. How-
ever, significant progress has been made in identifying
susceptibility genes to HT and AITD along with intriguing
findings regarding the functional characterization of dis-
ease-associated polymorphisms. These should stimulate
further studies towards the in-depth understanding of the
mechanisms by which these genes contribute to thyroid
autoimmunity.
Competing interests
The author(s) declare that they have no competing
interests.
Authors' contributions
ABFG
References
1. Vanderpump MP, Tunbridge WM: Epidemiology and prevention
of clinical and subclinical hypothyroidism.  Thyroid 2002,
12:839-847.
2. Wang C, Crapo LM: The epidemiology of thyroid disease and
implications for screening. Endocrinol Metab Clin North Am 1997,
26:189-218.
3. Tunbridge WM, Vanderpump MP: Population screening for
autoimmune thyroid disease.  Endocrinol Metab Clin North Am
2000, 29:239-253.
4. Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter
EW, Spencer CA, Braverman LE: Serum TSH, T4, and thyroid
antibodies in the United states population (1988 to 1994):
National health and Nutrition Examination Durvey
(NHALES III). J Clin Endocrind Metab 2002, 87:489-499.
5. Tunbridge WM, Evered DC, Hall R, Appleton D, Brewis M, Clark F,
Evans JG, Young E, Bird T, Smith PA: The spectrum of thyroid dis-
ease in a community: the Whickham survey. Clin Endocrinol
(Oxf) 1977, 7:481-493.
6. Okamura K, Ueda K, Sone H, Ikenoue H, Hasuo Y, Sato K, Yoshinary
M, Fujishima M: A sensitive thyroid hormone assay for screen-
ing a thyroid functional disorder in elderly Japanese. J Am Ger-
iatr Soc 1989, 37:317-322.
7. Gordin A, Heinonen OP, Saarinen P, Lamberg BA: Serum thyrotro-
pin in symptomless autoimmune thyroiditis.  Lancet 1972,
1:551-554.
8. Vanderpump MP, Tunbridge WM, French JM, Appleton D, Bates D,
Clark F, Grimley EJ, Hasan D, Rodgers H, Tunbridge F, Young ET:
The incidence of thyroid disorders in the community: a
twenty-year follow-up of the Whickham Survey. Clin Endocrinol
(Oxf) 1995, 43:55-69.
9. Hueston WJ: Treatment of hypothyroidism. Am Fam Physician
2001, 64:1717-1724.
10. Devendra D, Eisenbarth GS: 17. Immunological endocrine
disorders. J Allergy Clin Immunol 2003, 111:624-636.
11. Jenkins RC, Weetman AP: Disease associations with autoim-
mune thyroid disease. Thyroid 2002, 12:977-988.
12. Einarsdottir E, Soderstrom I, Lofgren-Burstrom A, Haraldsson S, Nils-
son-Ardnor S, Penha-Goncalves C, Lind L, Holmgren G, Holmberg M,
Asplund K, Holmberg D: The CTLA4 region as a general
autoimmunity factor: an extended pedigree provides evi-
dence for synergy with the HLA locus in the etiology of type
1 diabetes mellitus, Hashimoto's thyroiditis and Graves'
disease. Eur J Hum Genet 2003, 11:81-84.
13. Niederwieser G, Buchinger W, Bonelli RM, Berghold A, Reisecker F,
Koltringer P, Archelos JJ: Prevalence of autoimmune thyroiditis
and non-immune thyroid disease in multiple sclerosis. J Neurol
2003, 250:672-675.
14. Zettinig G, Tanew A, Fischer G, Mayr W, Dudczak R, Weissel M:
Autoimmune diseases in vitiligo: do anti-nuclear antibodies
decrease thyroid volume? Clin Exp Immunol 2003, 131:347-354.
15. Betterle C, Zanchetta R: Update on autoimmune polyendocrine
syndromes (APS). Acta Biomed Ateneo Parmense 2003, 74:9-33.
16. Rose NR, Saboori AM, Rasooly L, Burek CL: The role of iodine in
autoimmune thyroiditis. Crit Rev Immunol 1997, 17:511-517.
17. Rose NR, Bonita R, Burek CL: Iodine: an environmental trigger
of thyroiditis. Autoimmun Rev 2002, 1:97-103.
18. Tomer Y, Davies TF: Infection, thyroid disease and
autoimmunity. Endocrine Rev 1993, 14:107-120.
19. Mine H, Kawai H, Yokoi K, Akaike M, Saito S: High frequencies of
human T-lymphotropic virus type I (HTLV-I) infection and
presence of HTLV-II proviral DNA in blood donors with anti-
thyroid antibodies. J Mol Med 1996, 74:471-477.
20. Kakizaki S, Takagi H, Murakami M, Takayama H, Mori M: HLA anti-
gens in patients with interferon-alpha-induced autoimmune
thyroid disorders in chronic hepatitis C.  J Hepatol 1999,
30:794-800.
21. Imaizumi M, Pritsker A, Kita M, Ahmad L, Unger P, Davies T: Preg-
nancy and murine thyroiditis: thyroglobulin immunization
leads to fetal loss in specific allogeneic pregnancies. Endocrinol-
ogy 2001, 142:823-829.
22. Tomer Y: Genetic dissection of familial autoimmune thyroid
diseases using whole genome screening. Autoimmun Rev 2002,
1:198-204.
23. Boukis MA, Koutras DA, Souvatzoglou A, Evangepolou K, Vrontakis
M, Moulapoulaos SD: Thyroid hormone and immunologic stud-
ies in endemic goiter. J Clin Endocrinol Metab 1983, 57:859-862.
24. Harach HR, Eslacante DA, Onativia A, Lederer Outes J, Saravia Day
E, Williams ED: Thyroid carcinoma and thyroiditis in an
endemic goitre region before and after iodine phospholaxis.
Acta Endocrinol 1985, 108:55-60.
25. Allen EM, Appel MC, Braverman LE: The effect of iodide ingestion
on the development of spontaneous lympholytic thyroiditis
in the diabetesprone BB/W rat. Endocrinology 1986, 118:1977-81.
26. Rasooly L, Burek CL, Rose NR: Iodine-induced autoimmune thy-
roiditis in NOD-H-2h4 mice. Clin Immunol Immunopathol 1996,
81:287-292.
27. Ruwhof C, Draxhage HA: Iodine and thyroid autoimmune dis-
ease in animal models. Thyroid 2001, 11:427-436.
28. Kabel PJ, Voorbij HA, de Haan M, van der Gaag RD, Drexhage HA:
Intarthyroidal dendritic cells.  J Clin Endocrinol Metab 1988,
66:199-207.Journal of Autoimmune Diseases 2005, 2:1 http://www.jautoimdis.com/content/2/1/1
Page 16 of 21
(page number not for citation purposes)
29. Many M-C, Maniratunga S, Varis I, Dardenne M, Draxhage HA, Denef
J-F: Two-step development of a Hashimoto-like thyroiditis in
genetically autoimmune prone non-obese diabetic (NOD)
mice. Effects of iodine-induced cell necrosis. J Endocrinol 1995,
147:311-320.
30. Wan Q, Shah R, Panos JC, Giraldo AA, David CS, Kong YM: HLA-
DR and HLA-DQ polymorphism in human thyroglobulin-
induced autoimmune thyroiditis: DR3 and DQ8 transgenic
mice are susceptible. Hum Immunol 2002, 63:301-310.
31. Wan XL, Kimura A, Dong RP, Honda K, Tamai H, Sasazuki T: HLA-
A and -DRB4 genes in controlling the susceptibility to Hash-
imoto's thyroiditis. Hum Immunol 1995, 42:131-136.
32. Vasu C, Gorla SR, Prabhakar BS: Targeted engagement of
CTLA-4 prevents autoimmune thyroiditis. Int Immunol 2003,
15:641-654.
33. Greiner DL, Handler ES, Nakano K, Mordes JP, Rossini AA: Absence
of the RT-6 T cells in diabetes-prone BB/W rats. J Immunol
1986, 136:148-151.
34. Wick G, Brezinschek HP, Hala K, Dietrich H, Wolf H, Kroemer G:
The obese strain of chickens: an animal model for sponata-
neous autoimmune thyroiditis. Adv Immunol 1989, 47:433-500.
35. Martin A, Davies TF: T cells and human autoimmune thyroid
disease: emerging data show lack of need to invoke suppres-
sor T cell problems. Thyroid 1992, 2:247-261.
36. Bottazzo GF, Pujol-Borell R, Hanafusa T, Feldmann M: Role of aber-
rant HLA-DR expression and antigen presentation in induc-
tion of endocrine autoimmunity. Lancet 1983, 2:1115-1118.
37. Rapoport B, McLachlan SM: Thyroid autoimmunity. J Clin Invest
2001, 108:1253-1259.
38. Shimojo N, Kohno Y, Yamaguchi K, Kikuoka S, Hoshioka A, Niimi H,
Hirai A, Tamura Y, Saito Y, Kohn LD, Tahara K: Induction of
Graves-like disease in mice by immunization with fibroblasts
transfected with the thyrotropin receptor and a class II
molecule. Proc Natl Acad Sci USA 1996, 93:11074-11079.
39. Jaume JC, Guo J, Wang J, Rapoport B, McLachlan SM: Cellular thy-
roid peroxidase (TPO), unlike purified TPO and adjuvant,
induces antibodies in mice that resemble autoantibodies in
human autoimmune thyroid disease.  J Clin Endocrinol Metab
1999, 84:1651-1657.
40. Champion BR, Page KR, Parish N ,  R a yn e r  D C,  D a w e  K ,  B i s w a s -
Hughes G, Cooke A, Geysen M, Roitt IM: Identification of a thy-
roxine-containing self-epitope of thyroglobulin which trig-
gers thyroid autoreactive T cells. J Exp Med 1991, 174:363-370.
41. Rasooly L, Rose NR, Saboori AM, Ladenson PW, Burek CL: Iodine
is essential for human T cell recognition of human
thyroglobulin. Autoimmunity 1998, 27:213-219.
42. Ebner SA, Lueprasitsakul W, Alex S, Fang SL, Appel MC, Braverman
LE: Iodine content of rat thyroglobuline affects its autogenic-
ity in inducing lympholytic thyroiditis in the BB/Wor rat.
Autoimmunity 1992, 13:209-214.
43. Mahmoud I, Colin I, Many MC, Denef JF: Direct toxic effect effect
of iodide in excess on iodine-deficient thyroid gland: epithe-
lial necrosis and inflammation associated with lipofuscin
accumulation. Exp Mol Pathol 1986, 44:259-271.
44. Simons PJ, Delamarre FG, Drexhage HA: Antigen-presenting den-
dritic cells as regulators of the growth of thyrocytes: a role
for interleukin-1 beta and interleukin-6.  Endocrinology 1998,
139:3148-3156.
45. Lamas L, Anderson PC, Fox JW, Dunn JT: Consensus sequences
for early iodination and hormonogenesis in human
thyroglobulin. J Biol Chem 1989, 264:13541-13545.
46. Male DK, Champion BR, Pryce G, Matthews H, Shepherd P: Anti-
genic determinans of human thyreoglobulin differentiated
using antigen fragments. Immunology 1985, 54:419-427.
47. Tomer Y: Anti-thyroglobulin autoantibodies in autoimmune
thyroid diseases: cross-reactive or pathogenic? Clin Immunol
Immunopathol 1997, 82:3-11.
48. Kohno T, Tsinetoshi Y, Ishikawa E: Existence of antithyroglobulin
IgG in healthy subjects.  Biochem Biophys Res Commun 1988,
155:224-229.
49. Piechaszuk M, Bouananni M, Salhi SL, Baldet L, Bastide M, Pau B,
Bastide JM: Antigenic domains of the human thyroglobulin
molecule recognized by autoantibodies in patients' sera and
by natural autoantibodies isolated from sera of healthy
subjects. Clin Inmunol Immunopathol 1987, 45:114-121.
50. Dietrich G, Piechaszuk M, Pau B, Kasatchkine MD: Evidence for a
restricted idiotypic and epitopic specificity of anti-thyroglob-
ulin autoantibodies in patients with autoimmune thyroiditis.
Eur J Immunol 1991, 21:811-814.
51. Taneja V, David CS: HLA transgenic mice as humanized mouse
models of disease and immunity. J Clin Invest 1998, 101:921-926.
52. Kong YM, David CS, Lomo LC, Fuller BE, Motte RW, Giraldo AA:
Role of mouse and human class II transgenes in susceptibility
to and protection against mouse autoimmune thyroiditis.
Immunogenetics 1997, 46:312-317.
53. Dunn JT, Dunn AD: Update on the intrathyroidal iodine
metabolism. Thyroid 2001, 11:407-414.
54. McLachlan SM, Rapoport B: Genetic and epitopic analysis of thy-
roid peroxidase (TPO) autoantibodies: markers of the
human thyroid autoimmune response. Clin Exp Immunol 1995,
101:200-206.
55. Chardes T, Chapal N, Bresson D, Bes C, Giudicelli V, Lefranc MP,
Peraldi-Roux S: The human anti-thyroid peroxidase autoanti-
body repertoire in Graves' and Hashimoto's autoimmune
thyroid diseases. Immunogenetics 2002, 54:141-157.
56. Akamizu T: Antithyrotropin receptor antibody: an update. Thy-
roid 2001, 11:1123-1134.
57. Heufelder AE, Joba W, Morgenthaler NG: Autoimmunity involv-
ing the human sodium/iodide symporter: fact or fiction? Exp
Clin Endocrinol Diabetes 2001, 109:35-40.
58. Blucher H, Krohn K, Wallaschofski H, Braverman LE, Paschke R:
Cytokine gene expression in autoimmune thyroiditis in Bio-
Breeding/Worcester rats. Thyroid 1999, 9:1049-1055.
59. Mooij P, de Wit HJ, Drexhage HA: An excess of dietary iodine
accelerates the development of thyroid-associated lymphoid
tissue in autoimmune prone BB rats. Clin Immunol Immunopathol
1993, 69:189-198.
60. Blucher H, Krohn K, Wallaschofski H, Braverman LE, Paschke R: Fas
and Fas ligand gene expression in autoimmune thyroiditis in
BB/W rats. Eur J Endocrinol 1999, 141:506-511.
61. Salmaso C, Bagnasco M, Pesce G, Montagna P, Brizzolara R, Altrinetti
V, Richiusa P, Galluzzo A, Giordano C: Regulation of apoptosis in
endocrine autoimmunity: insights from Hashimoto's thy-
roiditis and Graves' disease. Ann N Y Acad Sci 2002, 966:496-501.
62. Weetman AP: Autoimmune thyroid disease: propagation and
progression. Eur J Endocrinol 2003, 148:1-9.
63. Eguchi K: Apoptosis in autoimmune diseases. Intern Med 2001,
40:275-284.
64. Stassi G, De Maria R: Autoimmune thyroid disease: new mod-
els of cell death in autoimmunity.  Nat Rev Immunol 2002,
21:195-204.
65. Giordano C, Richiusa P, Bagnasco M, Pizzolanti G, Di Blasi F, Sbriglia
MS, Mattina A, Pesce G, Montagna P, Capone F, Misiano G, Scorsone
A, Pugliese A, Galluzzo A: Differential regulation of Fas-medi-
ated apoptosis in both thyrocyte and lymphocyte cellular
compartments correlates with opposite phenotypic mani-
festations of autoimmune thyroid disease.  Thyroid 2001,
11:233-244.
66. Limachi F, Basso S: Apoptosis: life trough planned cellular death
regulating mechanisms, control systems, and relations with
thyroid disease. Thyroid 2002, 12:27-34.
67. Giordano C, Stassi G, De Maria R, Todaro M., Richiusa P, Papoff G,
Ruberti G, Bagnasco M, Testi R, Galluzzo A: Potential involvement
of Fas and its ligand in the pathogenesis of Hashimoto's
thyroiditis. Science 1997, 275:960-963.
68. Lowin B, Hahne M, Mattmann C, Tschopp J: Cytolytic T-cell cyto-
toxity is mediated through perforin and Fas lytic pathways.
Nature 1994, 370:650-652.
69. Arscott PL, Baker JR Jr: Apoptosis and thyroiditis. Clin Immunol
Immunopathol 1998, 87:207-217.
70. Zaccone P, Fehervari Z, Cooke A: Tumour necrosis factor-α  is a
fundamental cytokine in autoimmune thyroid disease
induced by thyroglobulin and lypopolysacharide in inter-
leukin-12 p40 deficient C57BL/6 mice.  Immunology 2003,
108:50-54.
71. Strasser A., O'Connor L, Dixit VM: Apoptosis signalling. Annu Rev
Biochem 2000, 69:217-245.
72. Bretz JD, Baker JR Jr: Apoptosis and autoimmune thyroid dis-
ease: following a TRAIL to thyroid destruction? Clin Endocrinol
2001, 55:1-11.Journal of Autoimmune Diseases 2005, 2:1 http://www.jautoimdis.com/content/2/1/1
Page 17 of 21
(page number not for citation purposes)
73. Hall R, Stanbury JB: Familial studies of autoimmune thyroiditis.
Clin Exp Immunol 1967, 2(Suppl):719-725.
74. Tomer Y, Davies TF: Searching for the autoimmune thyroid
disease susceptibility genes: from gene mapping to gene
function. Endocr Rev 2003, 24:694-717.
75. Brix TH, Kyvik KO, Hegedus L: A population-based study of
chronic autoimmune hypothyroidism in Danish twins. J Clin
Endocrinol Metab 2000, 85:536-539.
76. Ringold DA, Nicoloff JT, Kesler M, Davis H, Hamilton A, Mack T: Fur-
ther evidence for a strong genetic influence on the develop-
ment of autoimmune thyroid disease: the California twin
study. Thyroid 2002, 12:647-653.
77. Phillips DI, Osmond C, Baird J, Huckle A, Rees-Smith B: Is birth-
weight associated with thyroid autoimmunity? A study in
twins. Thyroid 2002, 12:377-380.
78. Rose NR: Avian models of autoimmune disease: lessons from
the birds. Poult Sci 1994, 73:984-990.
79. Lam-Tse WK, Lernmark A, Drexhage HA: Animal models of
endocrine/organ-specific autoimmune diseases: do they
really help us to understand human autoimmunity? Springer
Semin Immunopathol 2002, 24:297-321.
80. Stafford EA, Rose NR: Newer insights into the pathogenesis of
experimental autoimmune thyroiditis. Int Rev Immunol 2000,
19:501-533.
81. Braley-Mullen H, Johnson M, Sharp GC, Kuriakos M: Induction of
experimental autoimmune thyroiditis in mice with in vitro
activated splenic T cells. Cell Immunol 1985, 93:132-143.
82. Fuller BE, Giraldo AA, Waldmann H, Cobbold SP, Kong YC: Deple-
tion of CD4+ and CD8+ cells eliminates immunologic mem-
ory of thyroiditogenicity in murine experimental
autoimmune thyroiditis. Autoimmunity 1994, 19:161-168.
83. Caturegli P, Kuppers RC, Mariotti S, Burek CL, Pinchera A, Ladenson
PW, Rose NR: IgG subclass distribution of thyroglobulin anti-
bodies in patients with thyroid disease. Clin Exp Immunol 1994,
98:464-469.
84. Gebe JA, Swanson E, Kwok WW: HLA class II peptide-binding
and autoimmunity. Tissue Antigens 2002, 59:78-87.
85. Kong YM, Lomo LC, Motte RW, Giraldo AA, Baisch J, Strauss G,
Hammerling GJ, David CS: HLA-DRB1 polymorphism deter-
mines susceptibility to autoimmune thyroiditis in transgenic
mice: definitive association with HLA-DRB1*0301 (DR3)
gene. J Exp Med 1996, 184:1167-1172.
86. Flynn JC, Fuller BE, Giraldo AA, Panos JS, David CS, Kong JM: Flexi-
bility of TCR repertoire and permissiveness of HLA-DR3
molecules in experimental autoimmune thyroiditis in non-
obese diabetic mice. J Autoimmun 2001, 17:7-15.
87. Flynn JC, Wan Q, Panos JC, McCormick DJ, Giraldo AA, Davied CS,
Kong YM: Coexpression of susceptible and resistant HLA
class II transgenes in murine experimental autoimmune thy-
roiditis: DQ8 molecules downredulate DR3-mediated
thyroiditis. J Autoimmun 2002, 18:213-220.
88. Kong YM, David CS: New revelations in susceptibility to
autoimmune thyroiditis by the use of H2 and HLA class II
transgenic models. Int Rev Immunol 2000, 19:573-585.
89. Marguerie C, Lunardi C, So A: PCR-based analysis of the TCR
repertoire in human autoimmune diseases.  Immunol Today
1992, 13:336-338.
90. Matsuoka N, Bernard N, Concepcion ES, Graves PN, Ben-Nun A,
Davies TF: T-cell receptor V region beta-chain gene
expression in the autoimmune thyroiditis of non-obese dia-
betic mice. J Immunol 1993, 151:1691-1701.
91. Matsuoka N, Unger P, Ben-Nun A, Graves P, Davies TF: Thyroglob-
ulin-induced murine thyroiditis assessed by intrathyroidal T
cell receptor sequencing. J Immunol 1994, 152:2562-2568.
92. Quaratino S, Badami E, Pang YY, Bartok I, Dyson J, Kioussis D, Londei
M, Maiuri L: Degenerate self-reactive human T-cell receptor
causes spontaneous autoimmune disease in mice. Nat Med
2004, 10:920-926.
93. Quaratino S, Feldmann M, Dayan CM, Acuto O, Londei M: Human
self-reactive T cell clones expressing identical T cell receptor
β  chains differ in their ability to recognize a cryptic self-
epitope. J Exp Med 1996, 183:349-358.
94. Salomon B, Bluestone JA: Complexes of CD28/B7-CTLA-4 cos-
timulatory pathways in autoimmunity and transplantation.
Annu Rev Immunol 2001, 19:225-252.
95. Greenwald RJ, Boussotis VA, Lorsbach RB, Abbas AK, Sharpe AH:
CTLA-4 regulates induction of anergy in vivo. Immunity 2001,
14:145-155.
96. Eagar TN, Karandikar NJ, Bluestone JA, Miller SD: The role of
CTLA-4 in induction and maintaince of peripheral T cell
tolerance. Eur J Immunol 2002, 32:972-981.
97. Carreno BM, Bennett F, Chau TA, Ling V, Luxenberg D, Jussif J, Baroja
ML, Madrenas J: CTLA-4 (CD152) can inhibit T cell activation
by two different mechanisms depending on its level of cell
surface expression. J Immunol 2000, 165:1352-1356.
98. Prud'homme GJ, Chang Y, Li X: Immunoinhibitory DNA vaccine
protects against autoimmune diabetes through cDNA
encoding a selective CTLA-4 (CD152) ligand. Hum Gene Ther
2002, 13:395-406.
99. Campbell RD, Trowsdale J: Map of human MHC. Immunol Today
1993, 14:349-352.
100. Sakurami T, Ueno Y, Iwaki Y, Park MS, Terasaki PI, Saji H: HLA-DR
specificities among Japanese with several autoimmune
diseases. Tissue Antigens 1982, 19:129-133.
101. Hawkins BR, Lam KS, Ma JT, Wang CC, Yeung RT: Strong associa-
tion between HLA DRw9 and Hashimoto's thyroiditis in
Southern Chinese. Acta Endocrinol 1987, 114:543-546.
102. Ito M, Tanimoto M, Kamura H, Yoneda M, Morishima Y, Yamauchi K,
Itatsu T, Takatsuki K, Saito H: Association of HLA antigen and
restriction fragment length polymorphism of T cell receptor
beta-chain gene with Graves' disease and Hashimoto's
thyroiditis. J Clin Endocrinol Metab 1989, 69:100-104.
103. Inoue D, Sato K, Maeda M, Inoko H, Tsuji K, Mori T, Imura H:
Genetic differences shown by HLA typing among Japanese
patients with euthyroid Graves' ophthalmopathy, Graves'
disease and Hashimoto's thyroiditis: genetic characteristics
of euthyroid Graves' ophthalmopathy. Clin Endocrinol (Oxf) 1991,
34:57-62.
104. Inoue D, Sato K, Sugawa H, Akamizu T, Maeda M, Inoko H, Tsuji K,
Mori T: Apparent genetic difference between hypothyroid
patients with blocking-type thyrotropin receptor antibody
and those without, as shown by restriction fragment length
polymorphism analyses of HLA-DP loci. J Clin Endocrinol Metab
1993, 77:606-610.
105. Onuma H, Ota M, Sugenoya A, Fukushima H, Inoko H, Iida F: Asso-
ciation of HLA-DR53 and lack of association of DPB1 alleles
with Hashimoto's thyroiditis in Japanese. Tissue Antigens 1993,
42:150-152.
106. Moens H, Farid NR, Sampson L, Noel EP, Barnard JM: Hashimoto's
thyroiditis is associated with HLA-DRw3. N Engl J Med 1978,
299:133-134.
107. Weissel M, Hofer R, Zasmeta H, Mayr WR: HLA-DR and Hashim-
oto's thyroiditis. Tissue Antigens 1980, 16:256-257.
108. Farid NR, Sampson L, Moens H, Barnard JM: The association of
goitrous autoimmune thyroiditis with HLA-DR5.  Tissue
Antigens 1981, 17:265-268.
109. Thomsen M, Ryder LP, Bech K, Bliddal H, Feldt-Rasmussen U, Mol-
holm J, Kappelgaard E, Nielsen H, Svejgaard A: HLA-D in Hashim-
oto's thyroiditis. Tissue Antigens 1983, 21:173-175.
110. Tandon N, Zhang L, Weetman AP: HLA associations with Hash-
imoto's thyroiditis. Clin Endocrinol (Oxf) 1991, 34:383-386.
111. Stenszky V, Balazs C, Kraszits E, Juhasz F, Kozma L, Balazs G, Farid
NR:  Association of goitrous autoimmune thyroiditis with
HLA-DR3 in eastern Hungary. J Immunogenet 1987, 14:143-148.
112. Badenhoop K, Schwarz G, Walfish PG, Drummond V, Usadel KH,
Bottazzo GF: Susceptibility to thyroid autoimmune disease:
molecular analysis of HLA-D region genes identifies new
markers for goitrous Hashimoto's thyroiditis. J Clin Endocrinol
Metab 1990, 71:1131-1137.
113. Mangklabruks A, Cox N, DeGroot LJ: Genetic factors in autoim-
mune thyroid disease analyzed by restriction fragment
length polymorphisms of candidate genes.  J Clin Endocrinol
Metab 1991, 73:236-244.
114. Bogner U, Badenhoop K, Peters H, Schmieg D, Mayr WR, Usadel KH,
Schleusener H: HLA-DR/DQ gene variation in nongoitrous
autoimmune thyroiditis at the serological and molecular
level. Autoimmunity 1992, 14:155-158.
115. Shi Y, Zou M, Robb D, Farid NR: Typing for major histocompat-
ibility complex class II antigens in thyroid tissue blocks: asso-
ciation of Hashimoto's thyroiditis with HLA-DQA0301 and
DQB0201 alleles. J Clin Endocrinol Metab 1992, 75:943-946.Journal of Autoimmune Diseases 2005, 2:1 http://www.jautoimdis.com/content/2/1/1
Page 18 of 21
(page number not for citation purposes)
116. Nicholson LB, Wong FS, Ewins DL, Butler J, Holland A, Demaine AG,
McGregor AM: Susceptibility to autoimmune thyroiditis in
Down's syndrome is associated with the major histocompat-
ibility class II DQA 0301 allele.  Clin Endocrinol (Oxf) 1994,
41:381-383.
117. Barbesino G, Chiovato L: The genetics of Hashimoto's disease.
Endocrinol Metab Clin North Am 2000, 29:357-374.
118. Hunt PJ, Marshall SE, Weetman AP, Bunce M, Bell JI, Wass JA, Welsh
KI: Histocompatibility leucocyte antigens and closely linked
immunomodulatory genes in autoimmune thyroid disease.
Clin Endocrinol 2001, 55:491-499.
119. Petrone A, Giorgi G, Mesturino CA, Capizzi M, Cascino I, Nistico L,
O s b o r n  J ,  D i  M a r i o  U ,  B u z z e t t i  R :  Association of DRB1*04-
DQB1*0301 haplotype and lack of association of two poly-
morphic sites at CTLA-4 gene with Hashimoto's thyroiditis
in an Italian population. Thyroid 2001, 11:171-175.
120. Ban Y, Davies TF, Greenberg DA, Concepcion ES, Tomer Y: The
influence of human leucocyte antigen (HLA) genes on
autoimmune thyroid disease (AITD): results of studies in
HLA-DR3 positive AITD families. Clin Endocrinol 2002, 57:81-88.
121. Wu Z, Stephens HA, Sachs JA, Biro PA, Cutbush S, Magzoub MM,
Becker C, Schwartz G, Bottazzo GF: Molecular analysis of HLA-
DQ and -DP genes in Caucasoid patients with Hashimoto's
thyroiditis. Tissue Antigens 1994, 43:116-119.
122. Jenkins D, Penny MA, Fletcher JA, Jacobs KH, Mijovic CH, Franklyn
JA, Sheppard MC: HLA class II gene polymorphism contributes
little to Hashimoto's thyroiditis.  Clin Endocrinol (Oxf) 1992,
37:141-145.
123. Badenhoop K, Walfish PG, Rau H, Fischer S, Nicolay A, Bogner U,
Schleusener H, Usadel KH: Susceptibility and resistance alleles
of human leukocyte antigen (HLA) DQA1 and HLA DQB1
are shared in endocrine autoimmune disease. J Clin Endocrinol
Metab 1995, 80:2112-2117.
124. Bode HH, Dorf ME, Forbes AP: Familial lympholytic thyroiditis:
analysis of linkage with hitocompatibility and blood groups. J
Clin Endocrinol Metab 1973, 37:692-697.
125. Hawkins BR, Ma JT, Lam KS, Wang CC, Yeung RT: Analysis of link-
age between HLA haplotype and susceptibility to Graves'
disease in multiple-case Chinese families in Hong Kong. Acta
Endocrinol 1985, 110:66-69.
126. Roman SH, Greenberg D, Rubinstein P, Wallenstein S, Davies TF:
Genetics of autoimmune thyroid disease: lack of evidence
for linkage to HLA within families. J Clin Endocrinol Metab 1992,
74:496-503.
127. O'Connor G, Neufeld DS, Greenberg DA, Concepcion ES, Roman
SH, Davies TF: Autoimmunity 1993, 14:237-241.
128. Tomer Y, Barbesino G, Keddache M, Greenberg DA, Davies TF:
Mapping of a major susceptibility locus for Graves' disease
(GD-1) to chromosome 14q31.  J Clin Endocrinol Metab 1997,
82:1645-1648.
129. Barbesino G, Tomer Y, Concepcion ES, Davies TF, Greenberg DA: 1.
Selected immunoregulatory genes. International Consor-
tium for the Genetics of Autoimmune Thyroid Disease. J Clin
Endocrinol Metab 1998, 83:1580-1584.
130. Tomer Y, Barbesino G, Greenberg DA, Concepcion E, Davies TF:
Mapping the major susceptibility loci for familial Graves' and
Hashimoto's diseases: evidence for genetic heterogeneity
and gene interactions. J Clin Endocrinol Metab 1999, 84:4656-4664.
131. Tomer Y, Ban Y, Concepcion E, Barbesino G, Villanueva R, Greenberg
DA, Davies TF: Common and unique susceptibility loci in
Graves and Hashimoto diseases: results of whole-genome
screening in a data set of 102 multiplex families. Am J Hum
Genet 2003, 73:736-747.
132. Alkhateeb A, Stetler GL, Old W, Talbert J, Uhlhorn C, Taylor M, Fox
A, Miller C, Dills DG, Ridgway EC, Bennett DC, Fain PR, Spritz RA:
Mapping of an autoimmunity susceptibility locus (AIS1) to
chromosome 1p31.3-p32.2. Hum Mol Genet 2002, 11:661-667.
133. Maalej A, Makni H, Ayadi F, Bellassoued M, Jouida J, Bouguacha N,
Abid M, Ayadi H: A full genome screening in a large Tunisian
family affected with thyroid autoimmune disorders.  Genes
Immun 2001, 2:71-75.
134. Villanueva R, Tomer Y, Greenberg DA, Mao C, Concepcion ES, Tucci
S, Estilo G, Davies TF: Autoimmune thyroid disease susceptibil-
ity loci in a large Chinese family. Clin Endocrinol 2002, 56:45-51.
135. Sakai K, Shirasawa S, Ishikawa N, Ito K, Tamai H, Kuma K, Akamizu
T, Tanimura M, Furugaki K, Yamamoto K, Sasazuki T: Identification
of susceptibility loci for autoimmune thyroid disease to
5q31-q33 and Hashimoto's thyroiditis to 8q23-q24 by
multipoint affected sib-pair linkage analysis in Japanese. Hum
Mol Genet 2001, 10:1379-1386.
136. Levin L, Ban Y, Concepcion E, Davies TF, Greenberg DA, Tomer Y:
Analysis of HLA genes in families with autoimmune diabetes
and thyroiditis. Hum Immunol 2004, 65:640-647.
137. Torfs CP, King MC, Huey B, Malmgren J, Grumet FC: Genetic inter-
relationship between insulin-dependent diabetes mellitus,
the autoimmune thyroid diseases, and rheumatoid arthritis.
Am J Hum Genet 1986, 38:170-187.
138. Payami H, Joe S, Thomson G: Autoimmune thyroid disease in
type 1 diabetes. Genet Epidemiol 1989, 6:137-141.
139. Allen DB, MacDonald MJ, Gottschall JL, Hunter JB: Autoimmune
thyroid phenomena are not evidence for human lymphocyte
antigen-genetic heterogeneity in insulin-dependent
diabetes. Am J Med Genet 1989, 33:405-408.
140. Djilali-Saiah I, Bertin E, Larger E, Timsit J, Assan R, Boitard C, Bach JF,
Caillat-Zucman S: Major histocompatibility class II genes poly-
morphism in insulin dependent diabetes mellitus with or
without associated thyroid autoimmunity. Hum Immunol 1998,
59:176-182.
141. Fischer GF: Molecular genetics of HLA.  Vox Sanguinis 2000,
78:261-264.
142. Faas S, Trucco M: The genes influencing the susceptibility to
IDDM in humans. J Endocrinol Invest 1994, 17:477-495.
143. Sawai Y, DeGroot LJ: Binding of human thyrotropin receptor
peptides to a Graves' disease-predisposing human leukocyte
antigen class II molecule.  J Clin Endocrinol Metab 2000,
85:1176-1179.
144. Dawe KI, Hutchings PR, Geysen M, Champion BR, Cooke A, Roitt IM:
Unique role of thyroxine in T cell recognition of a pathogenic
peptide in experimental autoimmune thyroiditis.  Int Rev
Immunol 2000, 19:573-585.
145. Kuhr T, Hala K, Dietrich H, Herold M, Wick G: Genetically deter-
mined target organ susceptibility in the pathogenesis of
spontaneous autoimmune thyroiditis: aberrant expression
of MHC-class II antigens and the possible role of virus.  J
Autoimmun 1994, 7:13-25.
146. Kong JM: Graves' hyperthyroidism and thyroiditis in HLA-
DRB1*0301 (DR3) transgenic mice after immunization with
thyrotropin receptor DNA. Clin Exp Immunol 2004, 135:35-40.
147. Londei M, Lamb JR, Bottazzo GF, Feldmann M: Epithelial cells
expressing aberrant MHC class II determinants can present
antigen to cloned human T cells. Nature 1984, 312:639-641.
148. Hamilton F, Black M, Farquharson MA, Stewart C, Foulis AK: Spatial
correlation between thyroid epithelial cells expressing class
II MHC molecules and interferon-gamma-containing lym-
phocytes in human thyroid autoimmune disease.  Clin Exp
Immunol 1991, 83:64-68.
149. Shimojo N, Arima T, Yamaguchi K, Kikuoka S, Kohn LD, Kohno Y: A
novel mouse model of Graves' disease: implications for a
role of aberrant MHC class II expression in its pathogenesis.
Int Rev Immunol 2000, 19:619-631.
150. Platzer M, Neufeld DS, Piccinini LA, Davies TF: Induction of rat
thyroid cell MHC class II antigen by thyrotropin and gamma-
interferon. Endocrinology 1987, 121:2087-2092.
151. Nagataki S, Eguchi K: Cytokines and immune regulation in thy-
roid autoimmunity. Autoimmunity 1992, 13:27-34.
152. Todd JA: Genetic analysis of type 1 diabetes using whole
genome approaches. Proc Natl Acad Sci USA 1995, 92:8560-8565.
153. Lewin L, Tomer Y: The etiology of autoimmune diabetes and
thyroiditis: evidence for common genetic susceptibility.
Autoimmun Rev 2003, 2:377-386.
154. Makhatadze NJ: Tumor necrosis factor locus: genetic organisa-
tion and biological implications. Hum Immunol 1998, 59:571-579.
155. Milner CM, Campbell RD: Genetic organization of the human
MHC class III region. Front Biosci 2001, 6:D914-926.
156. Weetman AP, Ajjan RA, Watson PF: Cytokines and Graves
disease. Baillieres Clin Endocrinol Metab 1997, 11:481-497.
157. Chung JH, Cho BY, Lee HK, Kim TG, Han H, Koh CS: The tumor
necrosis factor beta * 1 allele is linked significantly to HLA-
DR8 in Koreans with atrophic autoimmune thyroiditis who
are positive for thyrotropin receptor blocking antibody.  J
Korean Med Sci 1994, 9:155-161.Journal of Autoimmune Diseases 2005, 2:1 http://www.jautoimdis.com/content/2/1/1
Page 19 of 21
(page number not for citation purposes)
158. De Nagel DC, Pierce SK: Heat shock proteins implicated in
antigen processing and presentation.  Semin Immunol 1991,
3:65-71.
159. Parkes AB, Darke C, Othman S, Thomas M, Young N, Richards CJ,
Hall R, Lazarus JH: Major histocompatibility complex class II
and complement polymorphisms in postpartum thyroiditis.
Eur J Endocrinol 1996, 134:449-453.
160. Fu Y, Yan G, Shi L, Faustman D: Antigen processing and autoim-
munity. Evaluation of mRNA abundance and function of
HLA-linked genes. Ann N Y Acad Sci 1998, 842:138-155.
161. Heward JM, Allahabadia A, Sheppard MC, Barnett AH, Franklyn JA,
Gough SC: Association of the large multifunctional proteas-
ome (LMP2) gene with Graves' disease is a result of linkage
disequilibrium with the HLA haplotype DRB1*0304-
DQB1*02-DQA1*0501. Clin Endocrinol 1999, 51:115-118.
162. Fling SP, Arp B, Pious D: HLA-DMA and -DMB genes are both
required for MHC class II/peptide complex formation in anti-
gen-presenting cells. Nature 1994, 368:554-558.
163. Kim TG, Carrington M, Choi HB, Kim HY, Han H: Three HLA-
DMB variants in Korean patients with autoimmune diseases.
Hum Immunol 1996, 46:58-60.
164. Ostrov DA, Shi W, Schwartz JC, Almo SC, Nathenson SG: Struc-
ture of murine CTLA-4 and its role in modulating T cell
responsiveness. Science 2000, 290:816-819.
165. Chistiakov DA, Turakulov RI: CTLA4 and its role in autoim-
mune thyroid disease. J Mol Endocrinol 2003, 31:21-36.
166. Vaidya B, Imrie H, Perros P, Young ET, Kelly WF, Carr D, Large DM,
Toft AD, McCarthy MI, Kendall-Taylor P, Pearce SH: The cytotoxic
T lymphocyte antigen-4 is a major Graves' disease locus. Hum
Mol Genet 1999, 8:1195-1199.
167. Tomer Y, Greenberg DA, Barbesino G, Concepcion E, Davies TF:
CTLA-4 and not CD28 is a susceptibility gene for thyroid
autoantibody production.  J Clin Endocrinol Metab 2001,
86:1687-1693.
168. Allahabadia A, Gough SC: The different approaches to the
genetic analysis of autoimmune thyroid disease. J Endocrinol
1999, 163:7-13.
169. Ueda H, Howson JM, Esposito L, Heward J, Snook H, Chamberlain G,
Rainbow DB, Hunter KM, Smith AN, Di Genova G, Herr MH, Dahl-
man I, Payne F, Smyth D, Lowe C, Twells RC, Howlett S, Healy B,
Nutland S, Rance HE, Everett V, Smink LJ, Lam AC, Cordell HJ,
Walker NM, Bordin C, Hulme J, Motzo C, Cucca F, Hess JF, Metzker
ML, Rogers J, Gregory S, Allahabadia A, Nithiyananthan R, Tuomile-
hto-Wolf E, Tuomilehto J, Bingley P, Gillespie KM, Undlien DE, Ron-
ningen KS, Guja C, Ionescu-Tirgoviste C, Savage DA, Maxwell AP,
Carson DJ, Patterson CC, Franklyn JA, Clayton DG, Peterson LB,
Wicker LS, Todd JA, Gough SC: Association of the T-cell regula-
tory gene CTLA4 with susceptibility to autoimmune disease.
Nature 2003, 423:506-511.
170. Magistrelli G, Jeannin P, Herbault N, Benoit De Coignac A, Gauchat
JF, Bonnefoy JY, Delneste Y: A soluble form of CTLA-4 gener-
ated by alternative splicing is expressed by nonstimulated
human T cells. Eur J Immunol 1999, 29:3596-3602.
171. Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, Tector AJ:
A native soluble form of CTLA-4.  Cell Immunol 2000,
201:144-153.
172. Manzotti CN, Tipping H, Perry LC, Mead KI, Blair PJ, Zheng Y, San-
som DM: Inhibition of human T cell proliferation by CTLA-4
utilizes CD80 and requires CD25+ regulatory T cells. Eur J
Immunol 2002, 32:2888-2896.
173. Oaks MK, Hallett KM: Cutting edge: a soluble form of CTLA-4
in patients with autoimmune thyroid disease. J Immunol 2000,
164:5015-5018.
174. Wang XB, Kakoulidou M, Giscombe R, Qiu Q, Huang D, Pirskanen R,
Lefvert AK: Abnormal expression of CTLA-4 by T cells from
patients with myasthenia gravis: effect of an AT-rich gene
sequence. J Neuroimmunol 2002, 130:224-232.
175. Huang D, Liu L, Noren K, Xia SQ, Trifunovic J, Pirskanen R, Lefvert
AK: Genetic association of Ctla-4 to myasthenia gravis with
thymoma. J Neuroimmunol 1998, 88:192-198.
176. Anjos S, Nguyen H, Ounissi-Benkalha H, Tessier MC, Polychronakos
C: A common autoimmunity predisposing signal peptide var-
iant of the cytotoxic T-lymphocyte antigen 4 results in inef-
ficient glycosylation of the susceptibility allele.  J Biol Chem
2002, 277:46478-46486.
177. Kouki T, Sawai Y, Gardine AC, Fisfalen ME, Alegre ML, DeGroot LJ:
CTLA-4 gene polymorphism at position 49 in exon 1 reduces
the inhibitory function of CTLA-4 and contributes to the
pathogenesis of Graves disease. J Immunol 2000, 165:6606-6611.
178. Maurer M, Loserth S, Kolb-Maurer A, Ponath A, Wiese S, Kruse N,
Rieckmann P: A polymorphism in the human cytotoxic T-lym-
phocyte antigen 4 (CTLA4) gene (exon 1 +49) alters T-cell
activation. Immunogenetics 2002, 54:1-8.
179. Holopainen PM, Partanen JA: Technical note: linkage disequilib-
rium and disease-associated CTLA4 gene polymorphisms. J
Immunol 2001, 167:2457-2458.
180. Kouki T, Gardine CA, Yanagawa T, Degroot LJ: Relation of three
polymorphisms of the CTLA-4 gene in patients with Graves'
disease. J Endocrinol Invest 2002, 25:208-213.
181. Ban Y, Davies TF, Greenberg DA, Kissin A, Marder B, Murphy B, Con-
cepcion ES, Villanueva RB, Barbesino G, Ling V, Tomer Y: Analysis
of the CTLA-4, CD28, and inducible costimulator (ICOS)
genes in autoimmune thyroid disease.  Genes Immun 2003,
4:586-593.
182. Wang XB, Zhao X, Giscombe R, Lefvert AK: A CTLA-4 gene pol-
ymorphism at position -318 in the promoter region affects
the expression of protein. Genes Immun 2002, 3:233-234.
183. Chen CY, Shyu AB: AU-rich elements: characterization and
importance in mRNA degradation.  Trends Biochem Sci 1995,
20:465-470.
184. Thomas M, Karlen S, D'Ercole , Sanderson C: Analysis of the 5' and
3' UTRs in the posttranslational regulation of the inter-
leukin-5 gene. Biochim Biophys Acta 1999, 1444:61-68.
185. Huang D, Giscombe R, Zhou Y, Pirskanen R, Lefvert AK: Dinucle-
otide repeat expansion in the CTLA-4 gene leads to T-cell
hyperreactivity via the CD28 pathway in myasthenia gravis.
J Neuroimmunol 2000, 105:69-77.
186. Takara M, Kouki T, DeGroot LJ: CTLA-4 AT-repeat polymor-
phism reduces the inhibitory function of CTLA-4 in Graves'
disease. Thyroid 2003, 13:1083-1089.
187. Anjos S, Polychronakos C: Mechanisms of genetic susceptibility
to type 1 diabetes: beyond HLA.  Mol Genet Metab 2004,
81:187-195.
188. Johnson GC, Esposito L, Barratt BJ, Smith AN, Heward J, Di Genova
G, Ueda H, Cordell HJ, Eaves IA, Dudbridge F, Twells RC, Payne F,
Hughes W, Nutland S, Stevens H, Carr P, Tuomilehto-Wolf E,
Tuomilehto J, Gough SC, Clayton DG, Todd JA: Haplotype tagging
for the identification of common disease genes.  Nat Genet
2001, 29:233-237.
189. Ling V, Wu PW, Finnerty HF, Agostino MJ, Graham JR, Chen S, Jussiff
JM, Fisk GJ, Miller CP, Collins M: Assembly and annotation of
human chromosome 2q33 sequence containing the CD28,
CTLA4, and ICOS gene cluster: analysis by computational,
comparative, and microarray approaches.  Genomics 2001,
78:155-168.
190. Zaletel K, Krhin B, Gaberscek S, Pirnat E, Hojker S: The influence
of the exon 1 polymorphism of the cytotoxic T lymphocyte
antigen 4 gene on thyroid antibody production in patients
with newly diagnosed Graves' disease.  Thyroid 2002,
12:373-376.
191. Vaidya B, Imrie H, Geatch DR, Perros P, Ball SG, Baylis PH, Carr D,
Hurel SJ, James RA, Kelly WF, Kemp EH, Young ET, Weetman AP,
Kendall-Taylor P, Pearce SH: Association analysis of the cyto-
toxic T lymphocyte antigen-4 (CTLA-4) and autoimmune
regulator-1 (AIRE-1) genes in sporadic autoimmune Addi-
son's disease. J Clin Endocrinol Metab 2000, 85:688-691.
192. Kristiansen OP, Larsen ZM, Pociot F: CTLA-4 in autoimmune dis-
eases – a general susceptibility gene to autoimmunity? Genes
Immun 2000, 1:170-184.
193. Harbo HF, Celius EG, Vartdal F, Spurkland A: CTLA4 promoter
and exon 1 dimorphisms in multiple sclerosis. Tissue Antigens
1999, 53:106-110.
194. Ligers A, Xu C, Saarinen S, Hillert J, Olerup O: The CTLA-4 gene
is associated with multiple sclerosis.  J Neuroimmunol 1999,
97:182-190.
195. Robles DT, Fain PR, Gottlieb PA, Eisenbarth GS: The genetics of
autoimmune polyendocrine syndrome type II.  Endocrinol
Metab Clin North Am 2002, 31:353-368.
196. Fakhfakh F, Maalej A, Makni H, Abid M, Jouida J, Zouali M, Ayadi H:
Analysis of immunoglobulin VH and TCR beta polymor-Journal of Autoimmune Diseases 2005, 2:1 http://www.jautoimdis.com/content/2/1/1
Page 20 of 21
(page number not for citation purposes)
phisms in a large family with thyroid autoimmune disorder.
Exp Clin Immunogenet 1999, 16:185-191.
197. Nakao Y, Matsumoto H, Miyazaki T, Nishitani H, Takatsuki K, Kasu-
kawa R, Nakayama S, Izumi S, Fujita T, Tsuji K: IgG heavy chain
allotypes (Gm) in autoimmune diseases. Clin Exp Immunol 1980,
42:20-26.
198. Uno H, Sasazuki T, Tamai H, Matsumoto H: Two major genes,
linked to HLA and Gm, control susceptibility to Graves'
disease. Nature 1981, 292:768-770.
199. Rasmussen AK: Cytokine actions on the thyroid gland. Dan Med
Bull 2000, 47:94-114.
200. Ajjan RA, Watson PF, Weetman AP: Cytokines and thyroid
function. Adv Neuroimmunol 1996, 6:359-386.
201. Hunt PJ, Marshall SE, Weetman AP, Bell JI, Wass JA, Welsh KI:
Cytokine gene polymorphisms in autoimmune thyroid
disease. J Clin Endocrinol Metab 2000, 85:1984-1988.
202. Blakemore AI, Watson PF, Weetman AP, Duff GW: Association of
Graves' disease with an allele of the interleukin-1 receptor
antagonist gene. J Clin Endocrinol Metab 1995, 80:111-115.
203. Pearce SH, Cheetham T, Imrie H, Vaidya B, Barnes ND, Bilous RW,
Carr D, Meeran K, Shaw NJ, Smith CS, Toft AD, Williams G, Kendall-
Taylor P: A common and recurrent 13-bp deletion in the
autoimmune regulator gene in British kindreds with autoim-
mune polyendocrinopathy type 1.  Am J Hum Genet 1998,
63:1675-1684.
204. Nithiyananthan R, Heward JM, Allahabadia A, Barnett AH, Franklyn
JA, Gough SC: A heterozygous deletion of the autoimmune
regulator (AIRE1) gene, autoimmune thyroid disease, and
type 1 diabetes: no evidence for association. J Clin Endocrinol
Metab 2000, 85:1320-1322.
205. Fournier C, Gepner P, Sadouk M, Charreire J: In vivo beneficial
effects of cyclosporin A and 1,25-dihydroxyvitamin D3 on the
induction of experimental autoimmune thyroiditis. Clin Immu-
nol Immunopathol 1990, 54:53-63.
206. Hahn HJ, Kuttler B, Mathieu C, Bouillon R: 1,25-Dihydroxyvitamin
D3 reduces MHC antigen expression on pancreatic beta-
cells in vitro. Transplant Proc 1997, 29:2156-2157.
207. Pani MA, Regulla K, Segni M, Krause M, Hofmann S, Hufner M, Herwig
J, Pasquino AM, Usadel KH, Badenhoop K: Vitamin D 1alpha-
hydroxylase (CYP1alpha) polymorphism in Graves' disease,
Hashimoto's thyroiditis and type 1 diabetes mellitus. Eur J
Endocrinol 2002, 146:777-781.
208. Pani MA, Regulla K, Segni M, Hofmann S, Hufner M, Pasquino AM,
Usadel KH, Badenhoop K: A polymorphism within the vitamin
D-binding protein gene is associated with Graves' disease but
not with Hashimoto's thyroiditis. J Clin Endocrinol Metab 2002,
87:2564-2567.
209. Ban Y, Taniyama M, Ban Y: Vitamin D receptor gene polymor-
phism is associated with Graves' disease in the Japanese
population. J Clin Endocrinol Metab 2000, 85:4639-4643.
210. Ban Y, Taniyama M, Ban Y: Vitamin D receptor gene polymor-
phisms in Hashimoto's thyroiditis. Thyroid 2001, 11:607-608.
211. Pani MA, Seissler J, Usadel KH, Badenhoop K: Vitamin D receptor
genotype is associated with Addison's disease. Eur J Endocrinol
2002, 147:635-640.
212. Fukazawa T, Yabe I, Kikuchi S, Sasaki H, Hamada T, Miyasaka K,
Tashiro K: Association of vitamin D receptor gene polymor-
phism with multiple sclerosis in Japanese. J Neurol Sci 1999,
166:47-52.
213. Gyorffy B, Vasarhelyi B, Krikovszky D, Madacsy L, Tordai A, Tulassay
T, Szabo A: Gender-specific association of vitamin D receptor
polymorphism combinations with type 1 diabetes mellitus.
Eur J Endocrinol 2002, 147:803-808.
214. Pedersen IB, Knudsen N, Jorgensen T, Perrild H, Ovesen L, Laurberg
P: Thyroid peroxidase and thyroglobulin autoantibodies in a
large survey of populations with mild and moderate iodine
deficiency. Clin Endocrinol 2003, 58:36-42.
215. Jaume JC, Guo J, Pauls DL, Zakarija M, McKenzie JM, Egeland JA,
Burek CL, Rose NR, Hoffman WH, Rapoport B, McLachlan SM: Evi-
dence for genetic transmission of thyroid peroxidase autoan-
tibody epitopic "fingerprints".  J Clin Endocrinol Metab 1999,
84:1424-1431.
216. Pirro MT, De Filippis V, Di Cerbo A, Scillitani A, Liuzzi A, Tassi V:
Thyroperoxidase microsatellite polymorphism in thyroid
diseases. Thyroid 1995, 5:461-464.
217. Cuddihy RM, Dutton CM, Bahn RS: A polymorphism in the extra-
cellular domain of the thyrotropin receptor is highly associ-
ated with autoimmune thyroid disease in females.  Thyroid
1995, 5:89-95.
218. Sunthornthepvarakul T, Kitvitayasak S, Ngowngarmaratana S, Kon-
thong P, Deerochanawong C, Sarinnapakorn V, Phongviratchai S:
Lack of association between a polymorphism of human thy-
rotropin receptor gene and autoimmune thyroid disease. J
Med Assoc Thai 1999, 82:1214-1219.
219. Tomer Y, Barbesino G, Greenberg DA, Concepcion E, Davies TF:
Linkage analysis of candidate genes in autoimmune thyroid
disease. III. Detailed analysis of chromosome 14 localizes
Graves' disease-1 (GD-1) close to multinodular goiter-1
(MNG-1). International Consortium for the Genetics of
Autoimmune Thyroid Disease.  J Clin Endocrinol Metab 1998,
83:4321-4327.
220. Allen EM, Hsueh WC, Sabra MM, Pollin TI, Ladenson PW, Silver KD,
Mitchell BD, Shuldiner AR: A genome-wide scan for autoim-
mune thyroiditis in the Old Order Amish: replication of
genetic linkage on chromosome 5q11.2-q14.3. J Clin Endocrinol
Metab 2003, 88:1292-1296.
221. Sale MM, Akamizu T, Howard TD, Yokota T, Nakao K, Mori T, Iwa-
saki H, Rich SS, Jennings-Gee JE, Yamada M, Bowden DW: Associa-
tion of autoimmune thyroid disease with a microsatellite
marker for the thyrotropin receptor gene and CTLA-4 in a
Japanese population. Proc Assoc Am Physicians 1997, 109:453-461.
222. Akamizu T, Sale MM, Rich SS, Hiratani H, Noh JY, Kanamoto N, Saijo
M, Miyamoto Y, Saito Y, Nakao K, Bowden DW: Association of
autoimmune thyroid disease with microsatellite markers for
the thyrotropin receptor gene and CTLA-4 in Japanese
patients. Thyroid 2000, 10:851-858.
223. Tomer Y, Greenberg DA, Concepcion E, Ban Y, Davies TF: Thy-
roglobulin is a thyroid specific gene for the familial autoim-
mune diseases. J Clin Endocrinol Metab 2002, 87:404-407.
224. Collins JE, Heward JM, Carr-Smith J, Daykin J, Franklyn JA, Gough SC:
Association of a rare thyroglobulin gene microsatellite vari-
ant with autoimmune thyroid disease. J Clin Endocrinol Metab
2003, 88:5039-5042.
225. Rivolta CM, Moya CM, Mendive FM, Targovnik HM: Genotyping
and characterization of two polymorphic microsatellite
markers located within introns 29 and 30 of the human thy-
roglobulin gene. Thyroid 2002, 12:773-779.
226. Ban Y, Greenberg DA, Concepcion E, Skrabanek L, Villanueva R,
Tomer Y: Amino acid substitutions in the thyroglobulin gene
are associated with susceptibility to human and murine
autoimmune thyroid disease.  Proc Natl Acad Sci U S A 2003,
100:15119-15124.
227. Ban Y, Tomer Y: The contribution of immune regulatory and
thyroid specific genes to the etiology of Graves' and Hashim-
oto's diseases. Autoimmunity 2003, 36:367-379.
228. Tomer Y, Greenberg D: The thyroglobulin gene as the first thy-
roid-specific susceptibility gene for autoimmune thyroid
disease. Trends Mol Med 2004, 10:306-308.
229. Wall JD, Pritchard JK: Haplotype blocks and linkage disequilib-
rium in the human genome. Nat Rev Genet 4:587-597.
230. Hutchings PR, Cooke A, Dawe K, Champion BR, Geysen M, Valerio
R, Roitt IM: A thyroxine-containing peptide can induce murine
experimental autoimmune thyroiditis.  J Exp Med 1992,
175:869-872.
231. Champion BR, Rayner DC, Byfield PGH, Page KR, Chan CTJ, Roitt JM:
Critical role of iodination for T cell recognition of thyroglob-
ulin in experimental murine thyroid autoimmunity. J Immunol
1987, 139:3665-3670.
232. Kacem HH, Rebai A, Kaffel N, Masmoudi S, Abid M, Ayadi H: PDS is
a new susceptibility gene to autoimmune thyroid diseases:
association and linkage study.  J Clin Endocrinol Metab 2003,
88:2274-2280.
233. Nilsson M: Iodide handling by the thyroid epithelial cell. Exp
Clin Endocrinol Diabetes 2001, 109:13-17.
234. Stuck BJ, Pani MA, Besrour F, Segni M, Krause M, Usadel KH, Baden-
hoop K: Fas ligand gene polymorphisms are not associated
with Hashimoto's thyroiditis and Graves' disease.  Hum
Immunol 2003, 64:285-289.
235. Park WS, Oh RR, Kim YS, Park JY, Lee SH, Shin MS, Kim SY, Kim PJ,
Lee HK, Yoo NY, Lee JY: Somatic mutations in the deathPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Journal of Autoimmune Diseases 2005, 2:1 http://www.jautoimdis.com/content/2/1/1
Page 21 of 21
(page number not for citation purposes)
domain of the Fas (Apo-1/CD95) gene in gastric cancer. J
Pathol 2001, 193:162-168.
236. Boldrini L, Loggini B, Gisfredi S, Zucconi Y, Baldinotti F, Fogli A, Simi
P, Cervadoro G, Barachini P, Basolo F, Pingitore R, Fontanini G:
Mutations of Fas (APO-1/CD95) and p53 genes in non-
melanoma skin cancer. J Cutan Med Surg 2003, 7:112-118.
237. Lynch RA, Wagoner L, Li S, Sparks L, Molkentin J, Dorn GW 2nd:
Novel and nondetected human signaling protein
polymorphisms. Physiol Genomics 2002, 10:159-168.
238. Barbesino G, Tomer Y, Concepcion ES, Davies TF, Greenberg DA:
Linkage analysis of candidate genes in autoimmune thyroid
disease. II. Selected gender-related genes and the X-chro-
mosome. International Consortium for the Genetics of
Autoimmune Thyroid Disease.  J Clin Endocrinol Metab 1998,
83:3290-3295.
239. Ban Y, Taniyama M, Tozaki T, Tomita M, Ban Y: Estrogen receptor
alpha dinucleotide repeat polymorphism in Japanese
patients with autoimmune thyroid diseases. BMC Med Genet
2000, 1:1.
240. Ban Y, Tozaki T, Taniyama M, Tomita M, Ban Y: Lack of association
between estrogen receptor beta dinucleotide repeat poly-
morphism and autoimmune thyroid diseases in Japanese
patients. BMC Med Genet 2001, 2:1.
241. Biunno I, Bernard L, Dear P, Cattaneo M, Volorio S, Zannini L, Bankier
A, Zollo M: SEL1L, the human homolog of C. elegans sel-1:
refined physical mapping, gene structure and identification
of polymorphic markers. Hum Genet 2000, 106:227-235.
242. Ban Y, Taniyama M, Tozaki T, Yanagawa T, Tomita M, Ban Y: SEL1L
microsatellite polymorphism in Japanese patients with
autoimmune thyroid diseases. Thyroid 2001, 11:335-338.
243. Field LL, Tobias R, Thomson G, Plon S: Susceptibility to insulin-
dependent diabetes mellitus maps to a locus (IDDM11) on
human chromosome 14q24.3-q31. Genomics 1996, 33:1-8.
244. Shirasawa S, Harada H, Furugaki K, Akamizu T, Ishikawa N, Ito K, Ito
K ,  T a m a i  H ,  K u m a  K ,  K u b o t a  S ,  H i r a t a n i  H ,  T s u c h i y a  T ,  B a b a  I ,
Ishikawa M, Tanaka M, Sakai K, Aoki M, Yamamoto K, Sasazuki T:
SNPs in the promoter of a B cell-specific antisense tran-
script, SAS-ZFAT, determine susceptibility to autoimmune
thyroid disease. Hum Mol Genet 2004, 13:2221-2231.
245. Tufarelly C, Stanley JAS, Carrick D, Sharpe JA, Ayyub H, Wood WG,
Higgs DR: Transcription of antisense RNA leading to gene
silensing and methylation as a novel cause of human genetic
disease. Nat Genet 2003, 34:157-165.
246. Rouault JP, Rimokh R, Tessa C, Paranhos G, Ffrench M, Duret L,
Garoccio M, Germain D, Samarut J, Magaud JP: BTG1, a member
of a new family of antiproliferative genes.  EMBO J 1992,
11:1663-1670.
247. Ahmad M, Srinivasula SM, Wang L, Talanian RV, Litwack G, Fern-
andes-Alnemri T, Alnemri ES: CRADD, a novel human apoptotic
adaptor molecule for caspase-2, and FasL/tumor necrosis
factor receptor-interacting protein RIP.  Cancer Res 1997,
57:615-619.
248. Delepine M, Pociot F, Habita C, Hashimoto L, Froguel P, Rotter J,
Cambon-Thomsen A, Deschamps I, Djoulah S, Weissenbach J, Nerup
J, Lathrop M, Julier C: Evidence of a non-MHC susceptibility
locus in type I diabetes linked to HLA on chromosome 6. Am
J Hum Genet 1997, 60:174-187.
249. Gaffney PM, Kearns GM, Shark KB, Ortmann WA, Selby SA, Malm-
gren ML, Rohlf KE, Ockenden TC, Messner RP, King RA, Rich SS, Beh-
rens TW: A genome-wide search for susceptibility genes in
human systemic lupus erythematosus sib-pair families. Proc
Natl Acad Sci U S A 1998, 95:14875-14879.
250. Van de Wetering M, Oosterwegel M, van Norren K, Clevers H: Sox-
4, an Sry-like HMG box protein, is a transcriptional activator
in lymphocytes. EMBO J 1993, 12:3847-3854.
251. Akamizu T, Hiratani H, Ikegami S, Rich SS, Bowen DW: Association
study of autoimmune disease at 5q23-q33 in Japanese
patients. J Hum Genet 2003, 48:236-242.
252. Walther A, Riehemann K, Gerke V: A novel ligand of the formyl
peptide receptor: annxin I regulates neutrophil extravasa-
tion by interacting with FRP. Mol Cell 2000, 5:831-840.
253. Lam E, Martin MM, Timerman AP, Sabers C, Fleischer S, Lukas T,
Abraham RT, O'Keefe SJ, O'Neill EA, Wiederrecht GJ: A novel
FK506 binding protein can mediate the immunosuppressive
effects of FK506 and is associated with the cardiac ryanodine
receptor. J Biol Chem 1995, 270:26511-26522.
254. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B: A model for
p53-induced apoptosis. Nature 1997, 389:300-305.
255. Flynn JC, Rao PV, Gora M, Alsharabi G, Wei W, Giraldo AA, David
CS, Banga JP, Kohn LD, Napolitano G, Singer DS, Molteni M, Scorza
R, Shimojo N, Kohno Y, Mozes E, Nakazato M, Ulianich L, Chung HK,
Matoba H, Saunier B, Suzuki K, Schuppert F, Saji M: Graves' disease:
a host defense mechanism gone awry. Int Rev Immunol 2000,
19:633-664.
256. Tomer Y, Barbesino G, Greenberg DA, Concepcion E, Davies TF: A
new Graves disease-susceptibility locus maps to chromo-
some 20q11.2. Am J Hum Genet 1998, 63:1749-1756.
257. Pearce SH, Vaidya B, Imrie H, Perros P, Kelly WF, Toft AD, McCarthy
MI, Young ET, Kendall-Taylor P: Further evidence for a suscepti-
bility locus on chromosome 20q13.11 in families with domi-
nant transmission of Graves disease. Am J Hum Genet 1999,
65:1462-1465.
258. Tomer Y, Concepcion E, Greenberg DA: A C/T single-nucleotide
polymorphism in the region of the CD40 gene is associated
with Graves' disease. Thyroid 2002, 12:1129-1135.
259. Watson PF, Pickerill AP, Davies R, Weetman AP: Analysis of
cytokine gene expression in Graves' disease and multinodu-
lar goiter. J Clin Endocrinol Metab 1994, 79:355-360.